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ABSTRACT 
Background:  The yeast Saccharomyces boulardii has been classed a probiotic because it is a live 
microorganism known to confer a health benefit to its host, with one such benefit being in the management of 
gastrointestinal disturbances like gastroenteritis.  Gastroenteritis is known to be the second leading cause of 
death in the world’s most vulnerable populations, with Rotavirus being the most common causative agent, 
responsible for 215,000 global child deaths during 2013.  Together with a few other probiotics, Saccharomyces 
boulardii has been considered a potentially viable treatment option having been associated with a decreased 
duration of diarrhea, decreased number of days to the first formed stool, and decreased duration of hospital stay 
in individual studies.  This systematic review was therefore designed to specifically investigate the effects of 
Saccharomyces boulardii on acute gastroenteritis caused by Rotavirus in the pediatric hospitalized patient.  
 
Objectives:  To assess the efficacy and safety of Saccharomyces boulardii in the treatment of acute 
gastroenteritis in the pediatric population.  Secondary objectives of cost -effectiveness in terms of length of 
hospital stay; optimal dosing and administration routes were also investigated.  
 
Methods: Data sources included Medline, CINAHL, Scopus and The Cochrane Library up to and including 
August 2015.  Only randomized controlled trials in a hospital setting and involving subjects less than 16 years 
were included.  Two reviewers independently evaluated studies for eligibility, quality and extracted the data.  
Data were analyzed using Review Manager 5 (RevMan 2008) software.  A random effects model of meta-
analysis was used due to the presence of heterogeneity of treatment effects between studies.   
 
Results: Out of a pool of 190 articles, 10 studies were selected for final inclusion and analysis.  A meta-analysis 
involving five of the ten included studies showed that Saccharomyces boulardii significantly shortened the 
duration of diarrhea (in days), compared to the control/placebo group (MD -0.57, 95%CI: -0.83 to -0.30, P < 
0.0001).  Also, participants were passing solid stools in the Saccharomyces boulardii group compared to the 
control group on Day 2 (RR 3.00; 95% CI: 0.32 to 27.87), Day 3 (RR 3.17; 95% CI: 1.89 to 5.31), Day 4 (RR 
1.63; 95% CI: 1.30 to 2.06) and Day 5 (RR 1.25; 95% CI: 1.08 to 1.44), (P = 0.06).  Other outcomes like number 
of participants having less than three stools per day during the intervention and duration of hospital stay did not 
produce any statistically significant results.  No studies reported on any significant adverse effects associated 
with the use of Saccharomyces boulardii. 
 
Conclusion: The results of the current systematic review appear to indicate there’s a potential benefit with using 
Saccharomyces boulardii to treat acute gastroenteritis in the pediatric patient.  Offering this unique yeast 
probiotic at a dose of 250mg once to twice per day for up to five days has shown some benefit and appears to 
be safe.  However, larger and more rigorous controlled trials  are needed to further investigate the efficacy and 
safety of individual probiotics, like Saccharomyces boulardii, in order to offer specific treatment guidelines. 
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OPSOMMING 
Agtergrond:  Die gis Saccharomyces boulardii word beskou as ‘n probiotika aangesien dit ‘n lewendige 
mikroorganisme is wat gesondheidsvoordele inhou vir die gasheer.  Een van die voordele is in die behandeling 
van gastrointestinale afwykings soos gastroenteritis. Alhoewel gastroenteritis slegs ‘n simptoom is van ‘n 
toestand, is dit bekend om die tweede mees algemene oorsaak van sterfte te wees onder vatbare populasies in 
die wêreld. Rotavirus, die mees algemene oorsaak van gastroenteritis, was verantwoordelik vir 215,000 
kindersterftes wêreldwyd tydens 2013.  Tesame met ‘n paar ander probiotika word Saccharomyces boulardii 
beskou as ‘n potensiële lewensvatbare behandelingsopsie.  Hierdie gis probiotika word in individuele studies 
geassosieer met ‘n verkorte duurte van diaree, verminderde aantal dae tot  die eerste gevormde stoelgang en ‘n 
verkorte duurte van hospitaal verblyf. Hierdie sistematiese literatuuroorsaak was dus beplan om die effek van 
Saccharomyces boulardii op akute gastroenteritis veroorsaak deur Rotavirus in pediatriese gehospitaliseerde 
pasiënte te ondersoek. 
 
Doelwitte:  Om die effektiwiteit en veiligheid van Saccharomyces boulardii in die behandeling van akute 
gastroenteritis in die pediatrie populasie te bepaal.  Sekondêre doelwitte was om die koste-effektiwiteit in terme 
van duurte van hospital verblyf, optimale dosering en administrasie roetes te ondersoek.  
 
Metodes: Data bronne het Medline, CINAHL, Scopus en die Cochrane Biblioteek tot en met Augustus 2015 
ingesluit.  Slegs verewekansigde gekontrolleerde proewe in ‘n hospitaal omgewing gedoen op persone jonger as 
16 jaar is ingesluit. Twee evalueerders het die studies onafhanklik evalueer vir geskiktheid, kwaliteit en was 
betrokke by data ekstraksie. Data was ge-analiseer deur gebruik te maak van Review Manager 5 (RevMan 
2008) sagteware. Die stogastiese-effekte model van meta-analise was gebruik as gevolg van die 
teenwoodigheid van heterogeniteit van behandelings-effekte tussen studies. 
 
Resultate: Uit ‘n poel van 190 potensiële artikels is 10 studies geselekteer vir finale insluiting en analise. ‘n 
Meta-analise op vyf van die tien studies het getoon dat Saccharomyces boulardii verantwoordelik was vir ‘n 
beduidende verkorte duurte van diaree (in dae), vergeleke met die kontrole of plasebo groepe (MD -0.57, 
95%CI: -0.83 to -0.30, P < 0.0001).  Resultate het ook gedui dat meer deelnemers in die Saccharomyces 
boulardii groep soliede stoelgane gehad het vergeleke met die kontrole groep op Dag 2 (RR 3.00; 95% CI: 0.32 
to 27.87), Dag 3 (RR 3.17; 95% CI: 1.89 to 5.31), Dag 4 (RR 1.63; 95% CI: 1.30 to 2.06) en Dag 5 (RR 1.25; 
95% CI: 1.08 to 1.44), (P = 0.06).  Ander uitkomste soos die aantal deelnemers met minder as drie stoelgange 
per dag gedurende intervensie en duurte van hospital verblyf het nie beduidende resultate gelewer nie.  Geen 
studies het enige newe-effekte geassosieer met die gebruik van Saccharomyces boulardii gerapporteer nie. 
 
Gevolgtrekking: Die resultate van die huidige sistematiese literatuuroorsig dui op ‘n potensiële voordeel met die 
gebruik van Saccharomyces boulardii vir die behandeling van akute gastroenteritis in die pediatriese groep.  Die 
inname van hierdie unieke gis probiotika teen ‘n dosis van 250mg een tot twee maal per dag vir tot vyf dae het 
op sommige voordele gewys en blyk om veilig te wees. Groter en strenger gekontrolleerde proewe word egter 
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aanbeveel om die effektiwiteit en veiligheid van individuele probiotika soos Saccharomyces boulardii verder te 
ondersoek ten einde spesifieke behandelingsriglyne te kan voorstel.   
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LIST OF DEFINITIONS 
Adverse event
1,2,3
: An adverse outcome that occurs during or after the use of a drug or other intervention but is 
not necessarily caused by it. 
 
Bias
1,2
: Bias is a systematic error, or deviation from the truth, which can lead to an underestimation or an 
overestimation of the true intervention effect. Biases can vary in magnitude – some are small and trivial 
compared to the observed effect, and some are substantial, so that an apparent finding may be entirely due to 
bias.  
 
Blinding
1,2
: [In controlled trials:] The process of preventing those involved in a trial from knowing to which 
comparison group a particular participant belongs.  The risk-of-bias is minimized when as few people as possible 
know who is receiving the experimental intervention and who the control intervention.  Participants, caregivers, 
outcome assessors, and analysts are all candidates for being blinded.   
 
Chi-squared test
1,2
: A statistical test based on comparison of a test statistic to a chi-squared distribution.  Used 
in RevMan analyses to test the statistical significance of the heterogeneity statistic.  
 
Clinically significant
1,2
: A result (e.g. a treatment effect) that is large enough to be of practical importance to 
patients and healthcare providers.   
 
Confidence Interval (CI)
1,2
: A measure of the uncertainty around the main finding of a statistical analysis.  
Estimates of unknown quantities are usually presented as a point estimate and a 95% confidence interval.  This 
means that if someone were to keep repeating a study in other samples from the same population, 95% of the 
confidence intervals from those studies would contain the true value of the unknown quantity.  Wider intervals 
indicate lower precision; narrow intervals, greater precision. 
 
Fixed-effect model
1,2
: [In meta-analysis:] A model that calculates a pooled effect using the assumption that all 
observed variation between studies is caused by the play of chance.  Studies are assumed to be measuring the 
same overall effect. 
 
Forest plot
1,2
: A graphical representation of the individual results of each study included in a meta-analysis 
together with the combined meta-analysis result.  The plot also allows readers to see the heterogeneity among 
the results of the studies.  The results of individual studies are shown as squares centered on each study’s point 
estimate.  A horizontal line runs through each square to show each study’s confidence interval – usually, but not 
always, a 95% confidence interval.  The overall estimate from the meta-analysis and its confidence interval are 
shown at the bottom, represented as a diamond.  The center of the diamond represents the pooled point 
estimate, and its horizontal tips represent the confidence interval.  
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Gastroenteritis (GE)
3,4
: Gastroenteritis refers to a wide variety of conditions characterized by infection or 
irritation of the digestive tract, particularly the stomach and intest ine.  Symptoms include nausea and vomiting, 
diarrhea and/or abdominal cramps.   These symptoms sometimes include fever and weakness.  The condition 
can be grouped according to length of episode i.e. a) “Acute” GE (AGE) if it lasts for less than 14 days, b)  
“Persistent” GE (PGE) if it lasts between 2 and 4 weeks, and c) “Chronic” GE (CGE) if it lasts for longer than 4 
weeks.  
 
Heterogeneity
1,2
: Used in a general sense to describe the variation in, or diversity of, participants, interventions, 
and measurement of outcomes across a set of studies, or the variation in internal validity of those studies.  Used 
specifically, as statistical heterogeneity, to describe the degree of variation in effect estimates from a set of 
studies.  It is also used to indicate the presence of variability among studies beyond the amount expected due 
solely to the play of chance. 
 
Intention-to-treat analysis (ITT)
1,2
: A strategy for analyzing data from a randomized controlled trial.  All 
participants are included in the arm to which they were allocated, whether or not they received (or completed) 
the intervention given to that arm.  ITT analysis prevents bias caused by the loss of participants.  
 
Mean difference
1,2
: The mean difference (more correctly ‘difference in means’) is a standard statistic which 
measures the absolute difference between the mean value in two groups in a clinical trial. It estimates the 
amount by which the experimental intervention changes the outcome on average compared with the control.  
 
Meta-analysis
1,2,5
: Meta-analysis is the use of statistical methods to summarize or combine the results of two or 
more independent studies. It can be used to combine the numerical results of all or some of the studies included 
in a systematic review. This yields an overall statistic, together with its confidence interval, that summarizes the 
effectiveness of the experimental intervention compared with the control intervention. The combination of 
intervention effects estimates across studies may incorporate an assumption that the s tudies are not all 
estimating the same intervention effect, but rather estimate intervention effects that follow a distribution across 
studies. This is then a random-effects meta-analysis. Alternatively, if it is assumed that each study is 
estimating exactly the same quantity, a fixed-effect meta-analysis is performed. 
 
P-value
1,2,5
: The probability (ranging from zero to one) that the results observed in a study (or results more 
extreme) could have occurred by chance if in reality the null hypothesis was true.  In a meta-analysis, the P 
value for the overall effect assesses the overall statistical significance of the difference between the intervention 
groups, whilst the P value for the heterogeneity statistic assesses the statistical significance of differences 
between the effects observed in each study. 
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Placebo
1,2
: An inactive substance or procedure administered to a participant, usually to compare its effects with 
those of a real drug or other intervention, but sometimes for the psychological benefit to the participant through a 
belief that s/he is receiving treatment.  Placebos are used in clinical trials to blind people to their treatment 
allocation.  Placebos should be indistinguishable from the active intervention to ensure adequate blinding.  
 
Random effects model
1,2
: A statistical model in which both within-study sampling error (variance) and between-
studies variation are included in the assessment of the uncertainty (confidence interval) of the results of a meta-
analysis.  When there is heterogeneity among the results of the included studies beyond chance, random-effects 
models will give wider confidence intervals than fixed-effect models. 
 
Randomization
1,2
: The process of randomly allocating participants into one of the arms of a controlled trial.  
There are two components to randomization: the generation of a random sequence, and its implementation, 
ideally in a way so that those entering participants into a study are not aware of the sequence (concealment of 
allocation). 
 
Randomized controlled trial (RCT)
1,2
: An experiment in which two or more interventions, possibly including a 
control intervention or no intervention, are compared by being randomly allocated to participants.   
 
Review Manager version 5 (RevMan5)
1,2
: Software developed for The Cochrane Collaboration to assist 
reviewers in preparing Cochrane Reviews.  Reviewers enter their protocols and reviews into RevMan, from 
which they are exported and sent to a Managing Editor to be considered for inclusion in the Cochrane Database 
of Systematic Reviews. 
 
Risk ratio (RR)
1,2
: The ratio of risk in two groups.  In intervention studies, it is the ratio of the risk in the 
intervention group to the risk in the control group.  A risk ratio of one indicates no difference between 
comparison groups.  For undesirable outcomes, a risk ratio that is less than one indicates that the intervention 
was effective in reducing the risk of that outcome. 
 
Saccharomyces boulardii
6,7
: A strain of yeast that has been investigated for its ability to mediate the response 
of gut protection, which is usually displayed by normal healthy gut flora.  It has displayed the ability to resist the 
action of gastric acid and bile, thereby making it a therapeutic agent for possibly the prevention and treatment of 
disorders affecting the gastrointestinal tract.     
 
Selective outcome reporting
1,2
: The selection of a subset of the original variables recorded, on the basis of the 
results, for inclusion in publication of trials. The particular concern is that statistically non-significant results might 
be selectively withheld from publication. 
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Sequence generation
1,2
: This principle addresses the allocation process in a randomized controlled trial (RCT). 
The starting point for an unbiased intervention study is the use of a mechanism that ensures that the same kinds 
of participants receive each intervention.  
 
Standard Deviation
1,2
: A measure of the spread or dispersion of a set of observations, calculated as the 
average difference from the mean value in the sample. 
 
Standard Mean Difference (SMD)
1,2
: The difference between two estimated means divided by an estimate of 
the standard deviation.  It is used to combine results from studies using different ways of measuring the same 
concept.  By expressing the effects as a standardized value, the results can be combined since they have no 
units.  Standardized mean differences are sometimes referred to as a d index.  
 
Statistically significant
1,2
: A result that is unlikely to have happened by chance.  The usual threshold for this 
judgment is that the results, or more extreme results, would occur by chance with a probability of less than 0.05 
if the null hypothesis was true.  Statistical tests produce a P value used to assess this. 
 
Systematic Review
1,2
: A systematic review attempts to collate all empirical evidence that fits pre-specified 
eligibility criteria in order to answer a specific research question. It uses explicit, systematic methods that are 
selected with a view of minimizing bias, thus producing more reliable findings from which conclusions can be 
drawn and decisions made. The key characteristics of a systematic review are: (i) a clearly stated set of 
objectives with pre-defined eligibility criteria for studies; (ii) reproducible methodology; (iii) a systematic search to 
identify all studies that would meet the eligibility criteria; (iv) an assessment of the validity of findings of included 
studies; (v) a systematic presentation and synthesis of the characteristics and findings of the included studies. 
Many systematic reviews contain meta-analyses (see meta-analysis). 
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LIST OF ABBREVIATIONS 
AAGE: Antibiotic-Associated Gastroenteritis 
AGE: Acute Gastroenteritis 
AIDS: Acquired Immune Deficiency Virus 
CFUs: Colony Forming Units 
CI: Confidence Interval      
DHAKA: Dehydration: Assessing Kids Accurately 
GE: Gastroenteritis 
GRADE: Grades of Recommendation, Assessment, Development and Evaluation 
HIV: Human Immuno-Deficiency Virus 
ITT: Intention-To-Treat 
MCEE: Maternal and Child Epidemiology Estimation Group 
MD: Mean Difference 
MDGs: Millennium Development Goals  
NNT: Numbers Needed to Treat 
OR: Odds Ratio 
ORS: Oral Rehydration Solution 
ORT: Oral Rehydration Therapy 
PGE: Persistent Gastroenteritis 
PROSPERO: Prospective Register of Ongoing Systematic Reviews  
RCTs: Randomized Controlled Trials    
RevMan5: Review Manager version 5 
RR: Risk Ratio, Relative Risk 
SCFAs: Short Chain Fatty Acids 
SD: Standard Deviation 
SDGs: Sustainable Development Goals       
SMD: Standard Mean Difference    
UNICEF: United Nations International Children’s Fund 
WMD: Weighted Mean Difference 
WGO: World Gastroenterology Organization 
WHO: World Health Organization 
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 CHAPTER 1 
BACKGROUND AND MOTIVATION FOR THE STUDY 
 
1.1 INTRODUCTION 
In September 2000, 189 countries, including South Africa, signed the United Nations Millennium Declaration, in 
an effort to address health concerns plaguing each of their populations, with a special focus on women and 
children.8,9  This declaration highlighted 8 goals called Millennium Development Goals (MDGs), each of which 
had country-specific tracking-of-progress for the period 1990 to 2015.8,9  One of the 8 goals, goal 4, was aimed 
at reducing child mortality by two-thirds, particularly the under-five mortality rate.8,9   
 
In 2015, the United Nations International Children’s Emergency Fund (UNICEF) reported a 53 percent decrease 
in the global under-five mortality rate, i.e. from 91 deaths-per-1000-live-births in 1990 to an estimated 43 deaths-
per-1000-live-births in 2015.8,9  Country-specific data was available and South Africa’s successful efforts to 
decrease under-five mortality rate were clearly shown.  Figure 1.1 below shows that this African state started off 
in 1990 with 61 deaths-per-1000-live-births, peaked in 2004 with 81 deaths-per-1000-live-births, followed by a 
dramatic drop to the current 44 deaths-per-1000-live-births.8  
 
 
Figure 1.1: South Africa’s children under-five mortality rate for the period 1990 to 2015, reflected as 
deaths-per-1000-live-births
8 
 
Although globally, fewer children under-five (12.7 million) have died since 1990, the 5.9 million children under-
five reported dead in 2015, equivalent to one child dying every 11 minutes, remains unacceptable.8,9,10  
Identifying the factors responsible for causing such a high mortality rate would therefore be paramount for 
achieving the MDGs of reducing the 1990 under-five mortality rate by two thirds by the year 2015.8,9,10   
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Although the successes of the MDGs resulted in progress in areas of poverty, access to improved sources of 
water, primary school enrollment and child mortality, other larger-scale challenges remain on the agenda of the 
world’s populations.8,11  Some of these challenges are not related to the current systematic review (e.g. 
addressing concerns around gender equality and getting every child into school), but others are directly related 
to the incidence of infectious diseases, i.e. ending world hunger and improving health services.  The approach 
that would best help with addressing these challenges has to be one that favors sustainability.  As a result, the 
idea of the 2015 Sustainable Development Goals (SDGs) was born.8,11 
 
The SDGs are described as new targets to replace the MDGs, with a target deadline for completion by the year 
2030.8,11  These SDGs were described as “a set of universally applicable goals that balance the three 
dimensions of sustainable development, i.e. environmental, social and economic”.  Specific to this review, the 
SDGs aim to end preventable deaths of newborns and children under-five years of age, reduce neonatal 
mortality to at least as low as 12 deaths-per-1000-live-births and under-five mortality to at least as low as 25 
deaths-per-1000-live-births.8,11   
 
To date and as reported by the World Health Organization (WHO) and the Maternal and Child Epidemiology 
Estimation Group (MCEE), the main causes of death in the under-five age group was found to be infectious 
diseases, prematurity and complications during labor and delivery.8,9,10  Globally, 45 percent of under-five deaths 
were during the neonatal period.  The remaining almost 50 percent of deaths in the under-five age group were 
attributable to the impact of infectious diseases.8,9,10 
 
A recent 2015 report issued by UNICEF also identified infectious diseases as the main culprits for causing 
disease and therefore death, amongst the under-five population.10  The top eight culprits in order of significance 
were identified as pneumonia, diarrhea/gastroenteritis (GE), sepsis, malaria, pertussis, measles, acquired 
immune deficiency virus (AIDS) and other causes.  In addition, these infectious diseases were found to have a 
lesser impact in low-mortality risk regions versus high-mortality risk regions, i.e. infectious diseases were 
responsible for 39 percent, 54 percent and 47 percent of all under-five deaths in South Asia, West and Central 
Africa, and Eastern and Southern Africa respectively.8,9,10  The leading cause of under-five deaths was attributed 
to pneumonia, with death due to GE being the second leading cause of death in this age group, contributing to 9 
percent, 10 percent and 10 percent of all under-five deaths in South Asia, Eastern and Southern Africa and West 
and Central Africa respectively.8,9,10  Despite being a symptom known to be both preventable and treatable, GE 
was still found to contribute between 5 to 10 percent of the total deaths in the under-five age group.8,9,10   
 
Initiatives aimed at improving drinking water, access to safe water, sanitation and hygiene, and access to 
vaccines and oral rehydration solutions (ORSs) have contributed positively to curbing the effects of this 
symptom.  However, GE still remains the second leading cause of death in the most vulnerable population.8,9,10 
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1.2 GASTROENTERITIS AND ITS MANY FORMS 
GE is not a disease/condition but rather a symptom of a disease/condition, resulting in it being difficult to 
formulate a description without being subjective.  As mentioned earlier, 2015 data released by UNICEF revealed 
that following pneumonia, GE was the second major cause of death, particularly in high-risk mortality regions 
and in the most vulnerable of groups.9  It was therefore imperative that a clear yet concise definition of GE be 
identified and universally accepted.  The WHO defined diarrhea/GE as “the passage of three or more loose or 
liquid stools per day, or more frequent passage than is normal for the individual”.4  It is important to mention that 
the consistency of stools and not so much the number, is also important in diagnosing GE.4,6,7,12,13  
 
1.2.1 Causes of Gastroenteritis 
There are numerous causative agents and accompanying mechanisms via which GE can be caused. 4,12,13  
According to the WHO4, there are four notable causes of GE which are briefly described below. 
 
1.2.1.1 Gastrointestinal infections 
Gastrointestinal infections may be caused by one of three organisms, i.e. bacterial, viral or parasitic.12,13  Ideally, 
identifying the likely cause of the infection on the basis of history and clinical findings is encouraged.  However, 
with more than twenty causative agents being associated with the development of GE (see Table 1.1 below), the 
cause of the GE is more than likely to be treated without the causative agent being identified. 12    
 
Table 1.1: Microbial agents commonly responsible for causing Gastroenteritis
12
 
Bacteria Diarrheagenic Escherichia coli, Campylobacter jejuni, Vibrio cholera O1, V. cholera O139, 
Shigella species, V. parahaemolyticus, Bacteroides fragilis, C. coli, C. upsaliensis, Nontyphoidal 
Salmonellae, Clostridium difficile, Yersinia enterocolitica, Y. pseudotuberculosis 
Viruses Rotavirus, Norovirus (calicivirus), Adenovirus (serotype 40/41), Astrovirus, Cytomegalovirus  
Parasites Protozoans: Cryptosporidium parvum, Giardia  intestinalis, Microsporidia, Entamoeba histolytica, 
Isospora belli, Cyclospora cayetanensis, Dientamoeba fragilis, Blastocystis hominis  
Helminths: Strongyloides stercoralis, Angiostrongylus costaricensis, Schistosoma mansoni, S. 
japonicum 
 
Specific to developing regions, both Rotavirus and Escherichia coli were found to be the two most common 
causative agents adding to the rate of occurrence of GE.4,9  However, the WHO reported that owing to the ease 
in which it can be transmitted (i.e. person-to-person contact and airborne droplet transmission), Rotavirus was 
found to be disproportionately implicated in severe cases that frequently needed hospitalization.  As illustrated in 
Figure 1.2 below, GE due to Rotavirus was found to be responsible for 215,000 (197,000 – 233,000) child 
deaths during 2013.4 
 
Stellenbosch University  https://scholar.sun.ac.za
 4 
 
 
Figure 1.2: 215,000 global child Rotavirus deaths
4
 
 
1.2.1.2 Malnutrition and contributing factors  
As defined by both the WHO and UNICEF, malnutrition refers to both under-nutrition and over-nutrition.4,9,10  
However, in the context of this review, it is a term used to refer to a state of nutrient deficiency .  The factors that 
result in malnutrition are predominantly related to the family and situation into which a child is born.  By way of 
example, violence, political instability and volatile economic conditions like that currently being experienced in 
some parts of the world, has resulted in that specific regions health systems being crippled and therefore unable 
to offer medical support to the population.4,9,10  Combined with poor diet, decreased accessibility/availability of 
food and an increased vulnerability to diseases/infections, the population’s risk of malnutrition steadily worsens.  
In such a scenario, the most at-risk population is the under-five age group.4,9,10   
 
According to the WHO and UNICEF data released in 2015, children from the poorest households are nearly two 
times as likely to die before the age of five as compared to their counterparts in richer households. 4,9,10  Data 
released by UNICEF describes the vast differences that exist in mortality rates in the under-five age group based 
on income levels.8-10  Strong emphasis is being placed by UNICEF and WHO that despite the progress shown 
by most countries in achieving the MDGs, there remains a huge disparity amongst the low-mortality and high-
mortality risk regions.4,8-10  These organizations report that a child born in a low-income country is, on average, 
11 times more likely to die before the age of five as a child in a high-income country.8,9,10  Malnutrition and its 
contributing factors were associated with 54 percent of child deaths (10.8 million children) and therefore remains 
a huge morbidity and mortality risk for the world’s youngest population.
4,8-10   
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1.2.1.3 Infant feeding practices 
Whether it is in a resource-rich or resource-restricted environment, breast-milk has the greatest impact on child 
mortality.8,9,13-16  Breast-milk is known to consist of essential and irreplaceable nutrition to support a child’s 
normal growth and development.9,15,16  Mechanisms that have been proposed as responsible for the positive 
protective effect of breastfeeding against GE and other infections include its antimicrobial or immunological 
properties – it contains hormones, anti-inflammatory factors, digestive enzymes and growth modulators which all 
help with protecting against infections.13-16  In addition, it can also protect an infant from the development of 
obesity and other non-communicable diseases.8,9,13-16   
 
A 2012 report released by UNICEF indicated that worldwide, developing countries only achieved a 37 percent 
exclusive breastfeeding rate amongst infants less than six months of age.8,9  Figure 1.3 below illustrates this and 
that fewer than half of newborns in developing countries benefitted from early initiation of breastfeeding (i.e. 
within the first hour of life).8,9     
 
 
Figure 1.3: Relative risk of pneumonia and diarrhea incidence and mortality for partial breastfeeding and 
not breastfeeding compared with that from exclusive breastfeeding among infants’ ages 0-5 months
8,9 
 
Even though it has been clearly documented that exclusive breastfeeding for the first six months of life offers 
maximum benefit, too few infants in developing countries are being exclusively breastfed for this period.8,9,13-16  
In September 2015, UNICEF released a publication highlighting key findings with regard to the MDGs and again 
found that only two out of five infants were put to the breast within an hour of birth, and only two out of five 
infants worldwide were exclusively breastfed for six months.8,9  Sub-Saharan Africa was only able to record a 34 
percent exclusively-breastfeeding rate during the period 2006 to 2012 (see Figure 1.4 below).8,9 
Stellenbosch University  https://scholar.sun.ac.za
 6 
 
 
 
 
Figure 1.4: Share of infants under six months of age who were exclusively breastfed, by region, 2006-
2010
8,9 
 
1.2.1.4 Compromised access to clean water and amenities 
One other MDG was to halve the proportion of the world’s population who did not have sustainable access to 
safe drinking water over the period 1990 to 2015.4,8-10  Although the 2015 WHO World Statistics Report revealed 
that an improved proportion of the global population has been afforded access to improved drinking-water 
sources, a MDG met globally in 2010, there were still 748 million people without improved access to clean 
sources of drinking water.  In addition, 14 percent of the world populations have no access to toilets, latrines or 
any form of sanitation, resulting in open defecation being practiced.4,8-10  
 
This is of particular importance as high levels of environmental contamination and pollution will result in 
increased exposure to numerous diseases and infections, which would inevitably result in the symptom of GE.  
Populations residing in low-income regions, which are already vulnerable to disease and infection, were found to 
also be the population without an improved sanitation facility.4,8-10 
 
1.2.1.5 Other factors 
Factors like person-to-person transmission, food contamination during preparation and storage under unhygienic 
conditions, contaminated water sources and contaminated fresh foods have been identified as possible causes 
of GE, although with a much smaller contributory role.4,8-10 
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1.2.2 Categories of Gastroenteritis 
According to the WHO4,10, GE can be broken down into four different clinical types based on duration and/or 
other distinguishing features, i.e.  
(1) acute GE (AGE) is GE that lasts for several hours or days with the main danger being dehydration;  
(2) acute bloody GE or dysentery which can result in damage to the intestinal mucosa, with accompanying 
sepsis, dehydration and malnutrition;  
(3) persistent GE (PGE) which is GE that lasts for 14 days or longer, with the main danger being 
malnutrition, dehydration and serious non-intestinal infection; and  
(4) GE with severe malnutrition with the main danger being severe systemic infection, dehydration, heart 
failure and vitamin/mineral deficiencies.4,10 
 
It is important to note that with each of these four clinical types of GE, dehydration is acknowledged as a 
common symptom.  The WHO defines dehydration as “a condition that results from excessive loss of body 
water”.4,9  This loss of body water is also accompanied by the loss of electrolytes like sodium, potassium, 
chloride and bicarbonate, a combination of which can be life-threatening if not corrected, especially in the 
vulnerable younger populations.   
 
Two of the earliest signs of an individual being dehydrated are the passage of dark-colored urine and ongoing 
thirst, signifying the body’s attempts to bring about hemodynamic stability by increasing water intake and 
decreasing water losses.  However, the longer the GE persists and the longer it is left untreated, the more 
significant the water and electrolyte losses and the more significant (and dangerous) the degree of dehydration.9  
This is especially true for the younger population.   
 
1.2.3 Prevention of Gastroenteritis 
The common goal of all healthcare groups, be it a community primary healthcare center or a global body like the 
WHO or UNICEF, would be to put in place measures to prevent a disease from occurring, as opposed to dealing 
with its management and associated complications.4  In addition to the enormous country saving-of-funds that 
could possibly be used towards other initiatives, prevention of a disease/condition would more importantly , save 
the patient and his/her family from the individual, health-associated and financial challenges that accompany a 
sick episode.9,10 
 
1.2.3.1 Increasing the coverage of Rotavirus vaccines 
In support of the impact of GE caused by the Rotavirus, 2012 UNICEF report indicated that Rotavirus remained 
the leading cause of severe under-five childhood GE.4,8-10  It was found to be responsible for an estimated 40 
percent of all hospital admissions due to GE and caused between 420,000 and 494,000 child deaths in 2008, 
predominantly in low-income regions, where the vaccine was mostly unavailable (see Figure 1.5 below).9 
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Figure 1.5: Share of countries that have introduced the Rotavirus vaccine into the entire country, by 
income group (per cent)
9
 
 
It is clear that the Rotavirus vaccine is effective in reducing under-five mortality by effectively reducing the risk of 
contracting the virus and therefore associated GE.9,10  However, concerted efforts need to be made so that the 
Rotavirus vaccine is made accessible to those groups most vulnerable (i.e. low-income countries).  In addition to 
the malnutrition associated with food insecurity that is experienced by children in low-income households, these 
children also have increased mortality-risk due to infections like pneumonia and GE.9,10  
 
1.2.3.2 Encouraging early and exclusive breastfeeding 
It is known that early and exclusive breastfeeding imparts numerous benefits to the infant and mother. 13-18  A 
study that is particularly relevant to this systematic review is that conducted by Plenge-Bönig et al in 2010.17  
These authors aimed to investigate the effect, if at all protective, of breastfeeding against  AGE caused by the 
Rotavirus infection.  The study took the form of a case-control design and extrapolated data of children ranging 
between 0 and 12 months from 30 pediatric practices across Europe, namely Germany, Switzerland and Austria.  
The case-control design was achieved by using Rotavirus-positive cases and Rotavirus-negative controls.  This 
resulted in the collection of 1256 stool samples, with 25 percent Rotavirus-positive and 75 percent Rotavirus-
negative.  These authors reported that being breastfed resulted in a reduced risk of AGE due to being Rotavirus-
positive (OR 0.53; 95% CI: 0.37 to 0.76).  Furthermore, younger infants (0 to 6 months of age) showed a 
stronger protective benefit (OR 0.33; 95% CI: 0.19 to 0.55) than the older group of infants (7 to 12 months of 
age).17  One might argue that even though the study by Plenge-Bönig et al (2010) produced results in support of 
breastfeeding for decreasing the risk of AGE caused by the Rotavirus, the study was conducted in a “privileged” 
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environment and used a “low-risk” sample population (i.e. infants residing in a first-world country, with access to 
a relatively acceptable standard of healthcare).17  As a result, can these findings be applied to populations who 
are deemed “higher-risk”? 
 
In contrast to the study above, Lamberti et al (2011) investigated the benefits of breastfeeding infants to 
decrease their risk of GE, but in countries considered developing nations.18  These reviewers conducted a 
systematic review to evaluate the association between the incidence of GE mortality and exclusive breastfeeding 
among children aged 6 to 23 months.  A large body of literature was found in support of the protective effects of 
breastfeeding against GE incidence, prevalence, hospitalizations, mortality and all -cause morbidity.  A random-
effects meta-analyses was applied to data from eighteen studies indicating varying degrees of protection across 
levels of breastfeeding exposure, with exclusive breastfeeding (from birth to 5 months) and breastfeeding (from 
6 to 23 months) offering the most benefit.  Not breastfeeding resulted in a 10.5 times higher risk of dying in the 0 
to 6 months age group, as compared to those exclusively breastfed.  Similarly, a statistically significant finding 
was found for breastfeeding protecting against GE in the 6 to 23 month age group who were breastfed versus 
those not (RR 2.18).18 
 
1.2.3.3 Promoting safe and hygienic practices and improving access to clean water 
The goal of hygiene promotion is to empower people with knowledge so that they understand the role hygienic 
practices play in disease- and infection-prevention.  According to a combined report by three global healthcare 
bodies, an estimated 663 million people across the globe, do not have access to an improved drinking-water 
source.10,19  In addition, about 1.9 billion people still retrieve their water supplies from sources contaminated by 
feces.   
 
By improving the access people have to water that is both safe for consumption and for supporting sanitation 
and hygiene, the mortality rate of the world’s  most vulnerable populations can be drastically reduced.  Programs 
like WHOs “WASH” aims to achieve just this, i.e. improve access to safe drinking-water, sanitation and hygiene 
services to these populations.19 
 
1.2.3.4 Promoting community-wide sanitation 
Simple but effective interventions that resulted in a decrease in GE incidence included: promoting safe disposal 
of human waste, hand-washing with soap, increasing access to safe water, improving water quality, advancing 
household water treatment and safe storage.10,19 
 
1.2.4 Treatment of Acute Gastroenteritis 
In addition to the provision of vaccinations (e.g. Rotavirus), the aim of treatment of AGE should include (a) 
preventing and reversing dehydration, (b) shortening the duration of the illness; and (c) reducing the period for 
which the patient is infectious.9,12,19 
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1.2.4.1 Prevent and reverse dehydration 
Dehydration not identified early and not treated timeously is known to have devastating consequences, 
especially in the most vulnerable younger age groups.9,12,19  Accurately assessing dehydration status is critical to 
determining the most appropriate treatment course.  However, no clinical diagnostic model/s for dehydration 
have been empirically derived and validated for use in resource-limited settings.  Global health bodies like the 
WHO and the World Gastroenterology Organization (WGO) have designed algorithms to aid with identifying and 
treating dehydration (see Table 1.2 below).12  However, the algorithm shown below was based largely on WHO 
expert opinion. 
 
Table 1.2: Assessment of degree of dehydration in patients with Gastroenteritis
12
 
 A B C 
Conditiona   Well, alert Restless, irritable Lethargic / unconscious 
Eyesb Normal Sunken Sunken 
Thirst Normal, not thirsty Thirsty, drinks eagerly Poorly / not able to drink 
Skin pinchc Goes back quickly Goes back slowly Goes back very slowly 
Decide: No signs of dehydration. ≥2 signs in B means some 
dehydration. 
≥2 signs in C means severe 
dehydration. 
Treat: Use treatment Plan A. Weigh the patient;  
Use Treatment Plan B. 
Weigh the patient;  
Use Treatment Plan C 
URGENTLY. 
a 
Lethargy and sleepy are not synonymous.  With lethargy, the child’s mental state is dull and the child cannot 
be fully awakened; the child may appear to be drifting into unconsciousness.  
b 
In some infants and children the eyes normally appear somewhat sunken.  It is helpful to ask the mother if 
the child’s eyes are normal or more sunken than usual.  
c 
The sk in pinch is less useful in infants or children with marasmus or kwashiorkor, or obese children.  Other 
signs that may be altered in children with severe malnutrition may include cool and moist extremities, 
weak/absent radial pulse and reduced/absent urine flow).  
 
Up until recently, there has been no study to derive stable clinical diagnostic models for dehydration in children 
with GE.  In 2015, a group of researchers conducted a prospective cohort study in Dhaka, to validate a 
dehydration scoring and decision tree model for children with GE.20  The study was referred to as the 
“Dehydration: Assessing Kids Accurately (DHAKA)” prospective cohort study, and randomly sampled children 
under-five with AGE.  A total 1025 children were eligible for inclusion, of which 850 were enrolled and 771 were 
included in the final analysis.  For each child, trained nursing staff assessed children for clinical signs of 
dehydration on the initial assessment, followed by serial weights as the children were rehydrated. 20   
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The authors determined the percent weight change with rehydration and used this to classify children with 
severe dehydration (>9 percent weight change), some dehydration (3 to 9 percent), or no dehydration (<3 
percent).  Using these clinical variables and logistic regression models, these authors developed the DHAKA 
dehydration tree model (see Figure 1.6 below) and the Dehydration Score (see Table 1.3 below).20 
 
 
Figure 1.6: DHAKA dehydration tree model
20
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Table 1.3: DHAKA dehydration score
20 
Assessment Plan A
a
 Plan B
b
 Plan C
c
 
General condition Normal Irritable/less active (*) Lethargic / comatose (*) 
Eyes Normal Sunken - 
Mucosa Normal Dry - 
Thirst Normal Thirsty Unable to drink (*) 
Radial pulse Normal Low Volume (*) Absent/uncountable (*) 
Skin turgor Normal Reduced (*) - 
Diagnosis No dehydration Some dehydration Severe dehydration 
At least two signs, 
including at least one key 
sign (*) are present 
Signs of ‘some 
dehydration’ plus at least 
one key sign (*) are 
present 
Treatment Prevent dehydration Rehydrate with ORS 
solution unless patient is 
unable to drink 
Rehydrate with IV fluids 
and ORS 
Reassess periodically Frequent reassessment More frequent 
reassessment 
One of three treatment plans may be followed based on the degree of dehydration into which the child is 
classified, i.e.  
a 
Plan A – no dehydration; outpatient management; continue breastfeeding; normal diet-for-age and 
encourage intake of fluids. 
b 
Plan B – some dehydration; observation in a healthcare facility for a minimum of 4 hours, rehydrate using 
oral rehydration solution (ORS) with the aim of providing 75ml/kg or the facilities rehydration protocol; 
observe changes in dehydration every 4 hours and repeat ORS administration until patient shows signs of 
being rehydrated. 
c 
Plan C – severe dehydration; inpatient status; resuscitation with intravenous fluid. 
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There are varied forms of rehydration protocols available, which are often determined by the resources available 
to the facility and the location thereof.  However, these protocols share common characteristics of taking into 
account the patients age, weight and degree of dehydration.  Table 1.4 below is an example of a rehydration 
protocol using ORS in the hospitalized patient, which is advocated for use by the WHO and WGO.12 
 
Table 1.4: Treating dehydration with Oral Rehydration Solution in hospitalized patients
12
  
Amount of Oral Rehydration Solution to be offered in the first 4 hours 
Age 
≤4 
Months 
4-11 months 
12-23 
months 
2-4 
Years 
5-14 
Years 
≥15 
Years 
Weight (kg) <5.0 5.0-7.9 8.0-10.9 11.0-15.9 16.0-29.9 ≥30.0 
ORS to offer 
(ml) 
200-400 400-600 600-800 800-1200 1200-2200 2200-4000 
 
ORS or oral rehydration therapy (ORT) is described as “the administration of appropriate solutions by mouth to 
prevent or correct diarrheal dehydration”.4,12  It consists of water and oral rehydration salts, which are supplied in 
specific amounts to compensate/partially compensate for losses in GE stools.  A typical ORS will consist of the 
following: sodium (75mmol/L), chloride (65mmol/L), anhydrous glucose (75mmol/L), potassium (20mmol/L), and 
trisodium citrate (10mmol/L) with an overall low osmolarity of 245mmol/L.  It can further be used as maintenance 
fluid therapy to compensate for ongoing losses once rehydration has been achieved. 4,12   
 
Despite being a cost-effective method of managing AGE and being able to reduce the burden on healthcare 
systems in both developed and developing countries, UNICEF reports that just over 40 percent of children 
under-five with GE received the recommended treatment of ORS.8-10  As is shown in Figure 1.7 below, South 
Asia and sub-Saharan Africa were found to be the regions with the lowest coverage of the ORS package, and 
interestingly also the regions with the most GE-related deaths.8-10 
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Figure 1.7: Coverage of the recommended Oral Rehydration Solution treatment package is low across 
regions, particularly in the ones with the highest mortal ity
8-10
 
 
1.2.4.2 Zinc supplementation 
Zinc is a micronutrient that is important for protein synthesis, cell growth and differentiation, immune function and 
the intestinal transport of water and electrolytes.9,12,21  Over time, the use of zinc supplementation has become 
synonymous with the management of AGE as it has been found to reduce the duration and severity of GE 
episodes and subsequent infections for up to three months.9,12,21   
 
In 2004, Fischer Walker & Black conducted a systematic review to estimate (in addition to other infections), the 
effect of zinc for the treatment of GE on GE mortality.21  A total of 13 studies were identified for abstraction and a 
meta-analysis was performed for all outcomes with ≥2 data points.  Zinc supplementation was found to decrease 
a number of parameters, i.e. the proportion of GE episodes which lasted more than 7 days, risk of 
hospitalization, all-cause mortality and GE mortality.  Zinc for the treatment of GE was estimated to decrease GE 
mortality by 23 percent.  The authors concluded that zinc was an effective treatment for GE and will decrease 
GE morbidity and mortality when used in low-income countries.21 
 
Conflicting results were provided by a Cochrane review conducted by Lazzerini & Ronfani.22  These reviewers 
conducted a review of 24 randomized controlled trials (RCTs) that compared oral zinc supplementation with 
placebo in children aged 1 month to 5 years with AGE or PGE, including dysentery.  Notably, the majority of the 
trials were conducted in Asia and in countries known to be at high-risk of a zinc deficiency.  Unlike previous 
reports, these authors reported that there was not enough evidence from well conducted RCTs to confirm that 
zinc supplementation during AGE reduced death or hospitalization.22 
 
Region assessed in years 2000 and 2015 
P
er
ce
nt
ag
e 
of
 c
ou
nt
rie
s 
pr
ov
id
in
g 
O
ra
l 
R
eh
yd
ra
tio
n 
S
ol
ut
io
n 
Stellenbosch University  https://scholar.sun.ac.za
 15 
 
In that same year, Lamberti et al (2013) conducted a systematic review and meta-analysis on the effect of oral 
zinc supplementation on AGE in children.23  Previous reviews confirmed the valuable role zinc supplementation 
played in treating and managing AGE, but these authors noted that  papers used in these reviews were all 
derived from South Asia.  This review included 104 papers, of which 15 sources were non-Chinese and 89 were 
Chinese.  The findings of this review confirmed the benefits of therapeutic zinc supplementation for GE among 
under-five children, in low- and middle-income countries, i.e. it reduced the duration of GE, stool output, stool 
frequency and length of hospital stay.  These findings were found to be consistent across Chinese and non-
Chinese studies as well as for non-specific and Rotavirus GE.23   
 
Recommendations from these reviews as well as others have shown that zinc supplementation offered as (10 to 
20mg per day) until GE has stopped, significantly reduced the severity and duration of GE in children under-
five.9,12,23  Furthermore, shorter courses of zinc supplementation (10 to 20mg per day for 10 to 14 days) 
decreased the incidence of GE for 2 to 3 months.  Both the WHO and UNICEF recommend zinc treatment for 10 
to 14 days as an adjunct therapy that reduces the duration and severity of GE and decreases the likelihood of 
subsequent infections for up to 3 months following treatment.4,9,12,23 
 
1.2.4.3 Ongoing breastfeeding and feeding 
The continuation of breastfeeding is of particular importance as both the antimicrobial and antibacterial effects of 
breastfeeding against GE infections have been well documented.15-16  Exclusive breastfeeding is known to 
protect against the common infections of infancy, decreases the frequency and severity of infectious episodes, 
and promotes the colonization of the intestinal ecosystem with beneficial bacteria (e.g. Bifidobacteria and 
Lactobacilli) rather than pathogenic bacteria.15,16,24-26   
 
It is therefore clear that the importance of interventions to promote, protect and support improved breastfeeding 
practices cannot be stressed enough, especially in resource-restricted regions and during the treatment of 
children suffering the effects of GE.9,16  Mothers should be educated by trained and skilled healthcare workers 
on the ongoing benefits of continued breastfeeding, especially during episodes of illness, like during GE.9,16  The 
full potential of breastfeeding in reducing mortality associated with GE and therefore overall child mortality can 
only be realized if all countries accelerate efforts to reach as many infants as possible with effective programs to 
improve breastfeeding.9,16  In addition, mothers and caregivers should be educated on the need to offer more 
frequent breastfeeds (or bottle feeds) to the recovering child.  There is no evidence supporting the use of special 
or diluted formulas.9,16 
 
During episodes of GE, it is common “unwarranted” practice to restrict the intake of other foods and fluids for 
more than 4 hours.  Normal feeding should be encouraged in those children who display no signs of 
dehydration.  In children who were initially identified as moderately to severely dehydrated, food should be 
started about 2 to 4 hours immediately after the dehydration has been corrected with ORS or intravenous 
rehydration.9,12,16  In terms of food and meals, infants and young children should be given age-appropriate foods 
offered as small but frequent meals throughout the day.  The energy intake should be advanced as the child is 
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able to tolerate an increased energy intake.  The only caution would be to limit the intake of solutions/fluids that 
have a high osmolar rate (e.g. canned fruit juices) which can aggravate GE.9,12,16 
 
1.3  THE LINK BETWEEN GASTROENTERITIS AND PROBIOTICS
 
The bacteria that are found in the gastrointestinal tract are a complex ecosystem and able to coexist with the 
host, as long as a state of balance (equilibrium) is maintained.6,7,14,15  However, during disruptions in this 
balanced state, clinical disorders and disease can result.  Gastrointestinal disorders, one of which being all 
forms of GE, can result in an imbalance.  One of the goals would then be to restore balance and one of the ways 
in which this could be done is by restoring the balance in the gastrointestinal bacteria’s ecosystem.6,7,14,15 
 
Probiotics have been identified as a possible treatment modality to restore beneficial gastrointestinal bacteria to 
its original balanced state.14,24-26  The definition of probiotics has evolved, mostly because probiotic bacteria can 
influence the physiological outcomes, distant from the gut.  Probiotics have therefore been defined as any 
“viable organism that (when ingested) have a beneficial effect in the prevention and treatment of specific 
pathological conditions”.14,24-26  In order for a probiotic to be viable and biologically active, it must be able to 
withstand the host’s natural defense barriers and arrive at the target site in an active form.
7,24-26  These 
microorganisms have been shown to act against enteric pathogens by competing for available nutrients and 
binding sites, increasing the acidity of gut contents, showing tolerance to high concentrations of ethanol and for 
releasing antimicrobial compounds.7,24-26    
 
The ability of an organism to be effective is strain-specific and therefore it is important for these microorganisms 
to be defined by their genus, species and strain.7,24-26  Research has shown that the human gastrointestinal tract 
contains a heterogenous mix of 1014 bacteria, of which <0.1 percent is yeast.7,24-26  The most referenced of all 
the human gut bacterium are the strains Lactobacillus acidophilus and Lactobacillus rhamnosus-GG.7,24-26   
 
Although yeast might account for only a minority of organisms making up the gut bacteria, each of their cell sizes 
is 10 times larger than that of bacteria, making yeast a stearic hindrance to pathogens. 7,24  Yeast can also be 
found in the stomach and colon, signifying their ability to thrive and survive in pH-varied mediums.  Owing to its 
ability to resist stresses like gastrointestinal enzymes, bile salts, varying pH, varying temperatures and organic 
acids, yeast has demonstrated the ability to play the same role as a probiotic .7,24 
  
1.3.1 The yeast probiotic Saccharomyces boulardii 
One of the most studied yeasts is the genus Saccharomyces, with about 20 different species and with 
applications in commercial settings involving bread making and alcoholic and dairy fermentation. 15,27,28  
However, it has also displayed a role in biological control with single-cell protein and vitamin production, 
synthesis of recombinant proteins and important antagonistic activities towards pathogenic bacteria and 
fungi.27,28   
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Saccharomyces cerevisiae variety boulardii, more commonly referred to as Saccharomyces boulardii, is a non-
pathogenic yeast that is suitable for human consumption and has also been considered for use in the treatment 
of inflammatory bowel disorders and several types of GE (e.g. antibiotic -associated diarrhea (AAGE), 
Clostridium-difficile-associated diarrhea, traveler’s diarrhea, tube-feeding diarrhea, chronic diarrhea in immuno-
compromised individuals and AGE) in adults and children.15,27,28 
 
1.3.2 Understanding the action of Saccharomyces boulardii 
According to Kelesidis & Pothoulakis6 (2012), there is evidence that resident gastrointestinal bacteria act as a 
major regulator of the immune system (i.e. the gut and other organs).  Saccharomyces boulardii has shown 
clinical and experimental effectiveness in inflammatory gastrointestinal diseases, indicating that these beneficial 
bacteria might interfere with signaling pathways.6,27-32  Saccharomyces boulardii’s mechanism of action has been 
noted to be three-fold, i.e. luminal, trophic on intestinal mucosa and regulation of the immune response.6,27-32 
 
1.3.2.1 Antimicrobial activity 
This yeast probiotic displays antimicrobial activity by inhibiting bacterial and parasitic growth, reducing gut 
translocation of pathogens, neutralizing bacterial virulence factors, and interfering with bacterial colonization by 
suppressing adherence to the host cell.6,27-32   
 
Additionally, Saccharomyces boulardii shows antitoxin effects by inhibiting toxin-receptor binding sites, 
stimulating antibody production against Clostridium-difficile toxin A, and allowing for direct proteolysis of 
pathogenic toxins.6,27-32  Saccharomyces boulardii is also able to exert a symbiotic relationship with resident 
microorganisms, thereby enhancing their survival and growth.  This allows for normal microbiota status to be 
reestablished more rapidly.6,27-32 
 
1.3.2.2 Trophic action 
The trophic action of Saccharomyces boulardii is numerous, i.e. it reduces the number of infected cells and 
stimulates the growth and differentiation of intestinal cells in response to trophic factors; it prevents apoptosis 
and/or synthesis of tumor necrosis factor-α; it reduces mucositis; it restores fluid transport pathways; it 
stimulates protein and energy production and restores metabolic activities in colonic epithelial cells.6,27-32 
 
In addition, this yeast probiotic has also shown the ability to secrete mitogenic factors that enhance cell 
restitution; it enhances the release of brush-border membrane enzymes; it stimulates the production of 
glycoproteins in the brush border; it stimulates the production of intestinal polyamines; and it is able to restore 
normal levels of colonic short chain fatty acids (SCFAs) .6,27-32 
 
Saccharomyces boulardii has also displayed an ability to help stabilize gastrointestinal barrier function by 
strengthening enterocyte tight junctions; by reducing crypt hyperplasia and cell damage in colitis models; and by 
decreasing intestinal permeability in Crohn’s disease patients.6,27-32 
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1.3.2.3 Effect on host’s immunity 
Innate immunity refers to a nonspecific defense mechanism that comes into play immediately or within a short 
space of time of an antigen appearing in the body.6,15,31  It can refer to physical barriers such as the skin, 
chemicals in the blood, as well as the cells making up the immune system and them being triggered once a 
foreign cell appears in the body.  Saccharomyces boulardii has displayed an ability to offer this innate immunity 
to the host by triggering the activation of complement.  This results in the migration of immune system cells like 
monocytes and granulocytes to the site of activation.  In addition, Saccharomyces boulardii used in an animal 
model, was able to enhance the number of Küpffer cells.6,15,31 
 
Adaptive immunity refers to a subsystem of the overall immune system that is composed of highly specialized, 
systemic cells and processes that eliminate or prevent pathogen growth.6,15,30-32  Saccharomyces boulardii was 
shown to complement the host’s adaptive immune system by enhancing the mucosal immune response and 
secretory immunoglobulin-A intestinal levels; enhancing the systemic immune response and levels of serum 
immunoglobulin-G to Clostridium difficile toxins A and B; helping with early production of interferon gamma, 
interleukin-12; stimulating regulatory T-cells; inhibiting dendritic cell-induced activation of T cells; and helping to 
modify the migration of lymphocytes in the chronic inflammatory bowel disease model and lymphocyte 
adherence to endothelial cells, improving cell rolling and adhesion.6,15,30-32 
 
This yeast probiotic was also studied for its ability to reduce pro-inflammatory responses and its ability to 
promote mucosal anti-inflammatory signaling effects.6,15,30-32  It was shown to decrease the expression of pro-
inflammatory cytokines like interleukin-8, interleukin-6, interleukin-1β, tumor necrosis factor-α and interferon-
gamma; it increased the anti-inflammatory cytokines like interleukin-10; and interfered with nuclear factor kappa-
mediated signal transduction pathways, in immune and colonic epithelial cells .6,15,31-32 
 
In addition, Saccharomyces boulardii was able to block the activation of extracellular signal-regulated kinases 
and mitogen-activated protein kinases; decreased nitric oxide and inhibited the production of inducible nitrous 
oxide; it modulated T-cell migratory behavior and increased the trapping of T-helper cells into mesenteric lymph 
nodes; and it also stimulated the production of anti-inflammatory molecules in human colonocytes.6,15,30-32 
 
1.3.3 The properties of Saccharomyces boulardii 
The site of action for Saccharomyces boulardii is most commonly the colon and the yeast probiotic has been 
shown to survive passage to its target organ.6,15,30-32  Most of the Saccharomyces strains have been shown to 
work optimally at temperatures between 220C to 300C – Saccharomyces boulardii however, is able to survive 
temperatures of up to 370C, and therefore able to survive human body temperatures.  Saccharomyces boulardii 
in a lyophilized form is able to survive gastric acid and bile.6,15,30-32   
 
Stool sampling tests done have shown that levels of Saccharomyces boulardii can be 100 to 1000 times lower 
than the oral dose offered, indicating that much of the oral dose is destroyed.  Despite this, researchers have 
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reported that although much of the oral dose consumed is destroyed, surviving doses have been found to be 
effective.6,15,30-32   
 
It is naturally resistant to antibiotics and proteolysis and able to survive in the competitive milieu of the intestinal 
tract.  In human subjects, the concentration in the colon was found to be dose-dependent.  When 
Saccharomyces boulardii was given to healthy subjects at doses used therapeutically (1 to 2 x 1010/d), colonic 
levels were found to be (2 x 108/gram) stool.  Furthermore, when offered orally, Saccharomyces boulardii was 
able to achieve steady-state concentrations within three days and was only cleared within 3 to 5 days after it had 
been discontinued.  It has also demonstrated an ability to coexist and thrive in the pres ence of other agents e.g. 
psyllium fiber increased Saccharomyces boulardii levels by 22 percent.6,15,30-32 
 
1.3.4 Clinical efficacy of Saccharomyces boulardii in disease states  
Research on the effects of Saccharomyces boulardii  on chronic conditions such as Crohn’s disease, ulcerative 
colitis, irritable bowel syndrome, parasitic infections, Amebic colitis, Giardiasis, Blastocytosis hominis, human 
immunodeficiency virus (HIV)-related diarrhea has been conducted but with no definite guidelines or 
recommendations.14,27  It has also featured in the management of more acute conditions like AAGE, Clostridium 
difficile infection, AGE, PGE, enteral nutrition-related GE, traveler’s GE and Helicobacter pylori infection.  For the 
purpose of this systematic review, the use of Saccharomyces boulardii in the management of GE will be 
investigated.14,27,28 
 
AAGE is defined as unexplained GE that occurs in association with the administration of antibiotics. 28-30  A 2010 
meta-analysis of ten RCTs involving adults showed that Saccharomyces boulardii was significantly protective for 
AAGE with a pooled relative risk (RR) of 0.47 (95% Confidence Interval (CI): 0.35 - 0.63, P < 0.001).29  An 
earlier meta-analysis involving five trials and 1076 participants showed similar results, with a significant 
protective effect being found in patients offered Saccharomyces boulardii (pooled RR 0.43; 95% CI: 0.23 - 
0.78).33   
 
When effects on the pediatric population were investigated, Kotowska et al (2005) found a significant increase in 
the prevention of AAGE in the Saccharomyces boulardii group compared to the controls, which ranged between 
7.6 and 30.1 percent respectively.34  Saccharomyces boulardii use in pediatric patients diagnosed with 
Clostridium difficile infection is rather limited.  One small observational study in children indicated that 
Saccharomyces boulardii may be effective in Clostridium difficile infection.27  But to date, there is not enough 
evidence to support routine use of such a probiotic in the prevention of Clostridium difficile infection.35   
 
Other papers have reported of a significant increase in SCFA concentrations in ten enteral-fed patients receiving 
Saccharomyces boulardii compared to 15 healthy controls.28-30  The relative significant reduction in enteral 
nutrition-related GE in the Saccharomyces boulardii group compared to the control ranged between 5 percent 
and 8.2 percent therefore warranting more studies to be done.28-30 
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Specific to the management of GE, Szajewska & Mrukowicz (2005) conducted a meta-analysis of five RCTs 
examining the effectiveness of Saccharomyces boulardii in preventing AAGE in a mixed adult and child 
population consisting of 1079 participants.32  Despite the cause of the GE differing from that of the current 
systematic review, these reviewers reported that Saccharomyces boulardii offered a significant reduced risk of 
developing AAGE from 17.2 percent to 6.7 percent when compared to the placebo group, i.e. (RR 0.43; 95% CI: 
0.23 to 0.78).  Although most of the participants in the included trials were being managed with antibiotics to 
treat respiratory tract infections, the reviewers concluded that Saccharomyces boulardii was moderately effective 
in preventing AAGE in both the adult and pediatric population.32 
 
More specific to the design of the current review is the study conducted by Szajewska, Skorka and Dylag 
(2007).33  These reviewers investigated the effectiveness of Saccharomyces boulardii in treating AGE in 
children, although the cause of the AGE was not pre-defined.  Five RCTs met the inclusion criteria stipulated by 
these reviewers.  A total of 619 participants were pooled into this systematic review and showed that offering a 
dose of Saccharomyces boulardii between 250 to 750mg per day and over a period of five to six days resulted in 
statistically significant changes in the Saccharomyces boulardii versus the control/placebo group, i.e. the 
duration of GE in the Saccharomyces boulardii group was statistically reduced compared to the control/placebo 
group (weighted mean difference (WMD) -1,1; 95% CI: -1.3 to -0.83; 4 studies).  In addition, Day 2 and Day 4 
were significant time points at which the participants in the Saccharomyces boulardii group showed possible 
cure of AGE when compared to their counterparts.  Participants receiving Saccharomyces boulardii were also 
less likely to experience GE on Day 3, Day 6 and Day 7 than the control group participants.  Overall, the 
intervention group showed a statistically significant reduction in the risk of GE that lasted more than seven days 
versus the control/placebo group.  These reviewers also reported that other outcomes like vomiting showed no 
statistical significance between groups, but the duration of hospitalization in the Saccharomyces boulardii was 
statistically lower compared to the control group.33   
 
1.3.5 The safety of Saccharomyces boulardii 
In 2005, a comprehensive review was conducted to establish the relationship between Saccharomyces boulardii 
and the development of a fungal infection called Saccharomyces fungemia.36  These authors reported of ninety 
two case reports of this Saccharomyces invasive infection, with patients requiring intravascular catheters and 
antibiotic therapy being the most frequent.  Saccharomyces boulardii was found to account for 51.3 percent of 
fungemias, all of which were isolated from blood samples.  The affected patients were found to be more 
frequently immunocompetent and with better prognosis, but each with a good response to intravenous 
amphotericin B and fluconazole.  The authors concluded that special caution should be taken when prescribing 
this yeast probiotic.36 
 
Specific to the pediatric patient, a single-case report highlighted a rare gastrointestinal allergic reaction after 
Saccharomyces boulardii was given to an infant.  However, this patient was already diagnosed with a food 
protein-induced enterocolitis.14,23 
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A 2010 systematic review reported that probiotic products like Saccharomyces boulardii have been shown to 
increase the risk of complications in “vulnerable” patients, like those that are immuno-compromised.37  Despite 
these reports, there have been no RCTs confirming any adverse effects observed with the use of 
Saccharomyces boulardii.   
 
Although there is growing research on the subject of probiotics in health, the multiple effects of confounders 
evident in these studies presents a challenge to researchers, making it difficult for them to make specific 
recommendations on its use in health and disease prevention.  Aside from factors directly related to the type of 
probiotic used (e.g. strain type, single versus multi-strain, dosage offered, route of administration), the cause of 
the condition under investigation might also vary.  In this case, GE can be as a result of either a bacterial, viral or 
parasitic cause.   
 
In order to develop clear and concise guidelines on the use of Saccharomyces boulardii to treat/manage AGE, 
research with more rigorous methodology is required.  According to research groups and organizations like The 
Cochrane Collaboration and The Centre for Evidence-based Medicine, the systematic review is considered 
evidence to be at the top of the research-hierarchy, i.e. level 1A evidence.1,38  Owing to the use of the gold 
standard RCT which can be accompanied with the completion of a meta-analysis, the systematic review also 
promotes the use of an appraisal system which appraises the quality of evidence according to important factors 
like directness, precision, and consistency.1,38 
 
1.4 DESCRIPTION OF A SYSTEMATIC REVIEW  
1.4.1 Description of a systematic review 
Systematic reviews are becoming increasingly popular as a way of summarizing research evidence.1,2  These 
reviews aim to answer a pre-defined research question by reviewing the best available related research after 
combining the results of several studies.  If done properly, systematic reviews are useful in establishing the 
clinical superiority, ethical appropriateness and cost effectiveness of an intervention.  Systematic reviews have 
the additional benefit of being replicated, especially as it is peer-reviewed.1,2  The characteristics of a high quality 
systematic review will identify all relevant published and unpublished evidence; select studies that adequately 
meet the pre-defined inclusion criteria; assess the quality of each included study; synthesize the findings from 
each individual study in an unbiased way; interpret the findings and present a balanced and impartial summary 
of the findings; and acknowledge any weaknesses in the evidence.   
 
When it comes to level of hierarchy of research designs, the systematic review is considered to be at the highest 
level in evaluating the effectiveness of interventions.  When possible, a meta-analysis may be conducted – 
however, while all meta-analyses are based on the systematic reviews of literature, not all systematic reviews 
necessarily include a meta-analysis.1,2 
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1.4.2 Steps in developing a systematic review 
Firstly, the problem that the reviewer is aiming to address should be specified in the form of a research question 
(or objective), which should clearly define the population of interest, the intervention to be investigated, the 
control group to be used and the outcomes to be reviewed.  In addition, the reviewer will also need to pre-define 
eligibility criteria consisting of both inclusion and exclusion criteria to be applied against studies for the review.1,2 
 
The next step would be to explicitly describe the exact steps that were followed during every stage of the review, 
making the likelihood of repeating it very possible.1,2  Every systematic review should aim to identify all studies 
that would meet the eligibility criteria.  Ideally, both published and unpublished literature should be searched for 
suitable studies relating to the intervention being investigated.  In order to maintain the integrity associated with 
conducting a systematic review, the literature search needs to be conducted in an unbiased manner so that all 
possible sources of literature are exhausted i.e. multiple databases are searched using a standardized or 
customized keyword search string.1,2  
 
In any high quality systematic review, the study design that is to be considered as a prerequisite for inclusion 
makes it a marker of quality.1,2 This is most applicable when working with randomized studies.  Assessing the 
quality of studies to be included in the systematic review needs to be practiced at every step of the review 
process.  This step is of particular importance as it needs to be conducted in a manner that minimizes any 
potential for bias, and is therefore carried out by a minimum of two reviewers, conducting assessments 
independently.  The use of checklists for the design-based quality will need to be applied rigorously to all 
selected studies.  Quality assessments will be used for exploring heterogeneity and informing decisions 
regarding suitability for a meta-analysis.  Applying the inclusion and exclusion criteria to selected studies is part 
of the appraisal of evidence and helps to guide reviewers in their decision to either include of exclude a study 
from the review.1,2 
 
Once this has been achieved, an assessment of the validity of the findings of the included studies should be 
done.1,2  This is often achieved by conducting a risk-of-bias assessment for each study and should be conducted 
independently by each of the reviewers.  The Cochrane Collaboration’s risk -for-bias tool using generation 
sequencing, allocation concealment, blinding, incomplete outcome data and loss to follow-up are some of the 
domains assessed.1,2   
 
In addition, the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) tool features 
in grading the quality of evidence. 1,2,38  The GRADE approach defines the quality of evidence for each individual 
outcome reported in a systematic review as the extent to which one can be confident that an estimate of effect or 
association is close to the quantity of specific interest. Quality of a body  of evidence involves consideration of 
within-study risk-of-bias (methodological quality), directness of evidence, heterogeneity, precision of effect 
estimates and risk of publication bias.1,2,38  
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The extraction of the relevant data from each individual study is important, and should be conducted 
independently by each of the reviewers.1,2  Extracted details might include information on authors, publication 
year, study design, study location, source of funding, duration of study, inclusion criteria, exclusion criteria, 
causes of the subject under investigation, number of subjects who completed the study, interventions 
investigated, outcomes, adverse effects and results.1,2  
 
The next step would be to synthesize the data that has been extracted – this consists of tabulating study 
characteristics (e.g. characteristics of included studies), quality and effects (e.g. summary of findings tables).1,2  
Furthermore, identifying the most suitable statistical methods to analyze the differences between studies and 
combining their effects will need careful thought.  Systematic presentation of the findings is crucial, and a meta-
analysis must always include a graphic visual display of the results .1,2 
 
The interpretation of these findings which will require the reviewer to assess studies for degree of quality, assess 
the included studies for risk of publication bias and related bias ’s, explore the heterogeneity amongst studies, 
and use these findings to offer recommendations.  In a systematic review or meta-analysis, assessing the 
outcomes would refer to interpreting the newfound results from the combined studies. This may then help 
describe the general trend that was observed, and new hypotheses can be formulated.1,2 
 
1.4.3 Strengths and weaknesses associated with a systematic review  
Systematic reviews and meta-analyses aim to answer a question by pooling together answers from different 
sources.1,2,38  A big challenge for such an attempt is to agree on the comparability of the collected data, in terms 
of the design, conduct and the presentation of data.  Issues such as size of studies, quality of the studies, 
randomization procedures and time spans should be comparable.  Nutritional studies are more difficult, 
particularly when compared to pharmacological experimental studies, in respect of controlling exposures, and to 
make sure that all subjects receive exactly the same exposures. In addition, the outcome data used in different 
studies are not always the same either.1,2,38 
 
Another challenge in conducting systematic reviews is to obtain all the relevant literature and to ensure a 
thorough and complete collection of all studies done on the subject .1,2,38  If all available literature is not included, 
the summary estimate may be misleading.  When the original studies included in the systematic review are of 
poor quality, the findings of the systematic review or meta-analysis conducted will also be of poor quality.  It is 
the responsibility of the author of the systematic review to include honest assessments of the study quality, the 
possible methodological flaws, the risk-of-bias and the comparability of the studies. This will allow for readers to 
interpret the results with caution, when necessary, and to bear these shortcomings in mind when drawing 
conclusions. Because of all these challenges, systematic reviews cannot replace clinical reasoning.1,2,38  
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1.4.4 Goal of systematic reviews  
In medical practice there is a need for clear and explicit recommendations based on solid facts .1,2,38 Without 
conducting a systematic review on a subject, decisions on what should be recommended will be made on 
personal opinion or hearsay, or on individual trials or single pieces of evidence, which can lead to bias and 
inaccurate conclusions.1,2,38 
 
The Cochrane Collaboration is an international initiative that aims to facilitate an evidence-based approach by 
bringing together scientific evidence.1  Its primary aim is to “help people make well-informed decisions about 
healthcare and health policy by preparing and maintaining high quality systematic reviews.” It is a non-profit 
organization and draws significantly on volunteer effort. The Cochrane Library  is published on behalf of The 
Cochrane Collaboration and includes systematic reviews done on medical topics.  Not all systematic reviews 
done are necessarily included in the Cochrane Collaboration – good systematic reviews can be conducted that 
are not Cochrane Reviews.1 
 
1.5 WHY IS IT IMPORTANT TO DO THIS REVIEW? 
There has been growing interest in the use of probiotics in the treatment of infectious conditions like GE owing to 
the characteristics of these microorganisms, i.e. they display an antagonistic behavior towards all things foreign 
in the body cavity, compete with such pathogens for binding sites and nutrients, produce and secrete multiple 
enzymes and chemicals to render the environment unsuitable for foreign bodies to grow and thrive, increase 
both innate and adaptive immune responses and for the most part, are not harmful .6,7,24-27  Collectively, there is a 
huge body of research in this area.  
 
Initially, systematic reviews and meta-analyses were conducted on the clinical applications of mostly probiotics 
and not so much on yeast-probiotics.  Sazawal et al (2006)39 conducted a meta-analysis of thirty four RCTs and 
reported that probiotics (multiple single strains) reduced the associated risk of AGE in children, but that the effect 
on AGE was dependent on the age of the host and the genera of the strain used.39  Johnston et al in their 
systematic review assessed the efficacy of probiotics in treating AAGE in 707 pediatric patients.25  This was 
followed five years later by a review of the same subject matter but in a pool of 3432 pediatric patients.26  The 
authors concluded that Lactobacillus rhamnosus and Saccharomyces boulardii at a high dose (5 to 40 billion 
colony-forming-units (CFUs)/d) may prevent the onset of AAGE, with no serious side effects, but that larger 
RCTs are required.25,26   
 
Specific to the younger population, a 2007 review conducted by Szajewska, Skorka & Dylag investigated the 
effectiveness of Saccharomyces boulardii in treating GE in children.33  This review consisted of data from five 
RCTs including children aged between 2 months and 12 years.  Off the five studies, only three were placebo-
controlled.  Participants were offered Saccharomyces boulardii at a dose ranging from (250 to 750mg/day) and 
this was offered over a period of five to six days.  The effect of Saccharomyces boulardii on duration of GE, stool 
output and percentage of participants with GE at specific cut-off points were assessed as primary outcomes, 
whilst secondary outcomes included vomiting, adherence to treatment and adverse effects.  The results for 
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similar outcomes were combined in a meta-analysis and revealed that the Saccharomyces boulardii group 
showed a significant reduction in duration of GE (WMD -1.1, 95% CI: -1.3 to -0.83; 4 RCTs) with a non-
significant test for heterogeneity.  Participants receiving Saccharomyces boulardii were also more likely to have 
GE resolution at Day 2 and Day 4, much sooner than their counterparts.  The Saccharomyces boulardii group 
also showed a statistically significant reduction in the risk of GE lasting more than seven days when compared to 
the control group.  These findings led the authors to conclude that Saccharomyces boulardii therapy for GE in 
healthy infants and children appears to provide a moderate benefit in terms of reducing the duration of GE.  
However, when the methodology of each of the included studies was scrutinized, it was evident that there were 
some discrepancies, i.e. three of the five included studies were not considered as having a low risk-of-bias; the 
bulk of the included studies did not adequately describe how allocation concealment was guaranteed; each of 
the five studies described withdrawals and drop outs; and only two of the five trials adequately described use of 
an intention-to-treat (ITT) analysis.  Owing to these methodological drawbacks, the authors recommended that 
the results obtained in this systematic review be considered with caution. 33 
 
Another systematic review of evidence for the use of probiotics in the management of AGE was conducted in 
2010 by Allen et al.15  Following a comprehensive search of the literature on multiple databases, sixty three 
RCTs met the pre-specified inclusion criteria and this included 8014 participants, both adult and pediatric.  
Overall the primary outcome of a reduction in the duration of GE was evident, i.e. 39.1 hours in the probiotic 
group versus 173.5 hours in the control group.  Probiotics reduced the mean duration of GE (mean difference 
(MD) 24.76 hours; 95% CI: 15.9 to 33.6 hours; n=4555; 35 trials); intervention groups were found to have a 59 
percent reduced risk of experiencing GE for ≥4 days when compared to control groups (RR 0.41; 95% CI: 0.32 
to 0.53; n=2853; 29 trials); and use of probiotics resulted in a decreased stool frequency on Day 2 (MD 0.80; 
95% CI: 0.45 to 1.14; n=2751; 20 trials).15  These reviewers did recommend though that their results should be 
considered with caution owing to the many different probiotics tested.  Off the sixty three included studies, forty 
six tested a single organism and seventeen tested combinations ranging between two and eight organisms.  
Although Saccharomyces boulardii together with Lactobacillus casei-GG and Enterococcus lactic acid bacteria 
were identified as the most common organisms, the true effect of the yeast probiotic cannot be extrapolated from 
this data.  Overall, the pooled results of this 2010 systematic review indicated that probiotics in addition to 
rehydration therapy resulted in reductions in the duration and severity of GE, and with no adverse effects being 
reported.15  The difficulties presented by this review lie in the differences attached to each of the included 
studies, i.e. the study population consisted of a varied mixture of adult, pediatric and infant patients.  Although 
the primary outcome assessed was duration of GE, a universal definition for GE and resolution thereof was not 
used, thereby adding to the subjectivity of the results reported in each individual study.  There is general 
consensus that the effects of probiotics are strain-specific and that results obtained with one probiotic cannot be 
used to explain the effects of other strains.  This review by Allen et al included a pooled analysis of results 
obtained from the use of multiple probiotic strains, which were also offered in different settings .  Although 
beneficial outcomes were identified, each of the probiotic strains used are likely to have multiple mechanisms of 
action.15   This means that the effect/s it has/had on the host’s immunity and gut mucosal barrier integrity will 
vary.  Furthermore, the efficacy of each probiotic might have been impacted on by the environment in which it 
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was offered.  These authors acknowledged the vast heterogeneity that was found between studies and therefore 
concluded that it would be difficult to use this information to develop evidence-based treatment guidelines.15 
 
In that same year, McFarland (2010) conducted a systematic review and meta-analysis of Saccharomyces 
boulardii, but in the adult population.29  Thirty one RCTs, which were not restricted by language, were used in a 
meta-analysis which yielded a study population of 5029 participants.  Saccharomyces boulardii was found to be 
significantly effective and safe in 84 percent of the treatment arms.  When the types of GE were more closely 
examined, the author found that Saccharomyces boulardii was particularly effective in preventing AAGE, i.e. 
adult patients with a background of receiving antibiotic therapy and offered Saccharomyces boulardii 
prophylactically, were 53 percent less likely to experience AAGE as compared to those patients not receiving 
Saccharomyces boulardii (RR 0.47; 95% CI: 0.35 to 0.63; P < 0.001).  Unlike the previous systematic review, 
this reviewer reported that Saccharomyces boulardii was both safe and beneficial for use in the adult population.  
Furthermore, recommendations for its use for specific infectious condit ions was suggested, with a typical daily 
dose of >109 CFUs/day.  Based on the disease state, the yeast probiotic could be offered for a minimum of 
seven days, up to six months, and either as a single treatment modality or as adjunct treatment.  However, for 
more chronic disease states (e.g. Crohns disease, irritable bowel syndrome), the reviewer recommended that 
more RCTs are needed.29 
 
The systematic review conducted by Pan et al (2012) was perhaps the only piece of literature that best mimicked 
the study design of the current systematic review.40 These authors also assessed the effect of either placebo/no 
additional intervention versus Saccharomyces boulardii on children with AGE, with primary outcomes being 
duration of GE, stool frequency and adverse effects.  A total of eight RCTs met the inclusion criteria warranting 
advancement to analysis and pooling of data.  The eight included studies resulted in a pooled sample population 
of 978 children ranging between the ages of 1 month and 12 years.  The intervention group consisted of 487 
participants receiving the yeast probiotic (250 to 500mg per day), versus the control group consisting of 491 
participants.  The results of the meta-analysis showed that Saccharomyces boulardii was more effective in 
decreasing the duration of GE compared to the control group (MD -0.92; 95% CI: -1.32 to -0.52).  This was 
especially applicable for stool frequency on Day 3 (MD -1.92, 95% CI: -1.63 to -0.95), Day 4 (MD -0.51; 95% CI: 
-0.89 to -0.33), and Day 7 (MD -0.44; 95% CI: -0.72 to -0.16).  In addition, none of the included studies reported 
on any adverse events occurring.  These authors therefore concluded that Saccharomyces boulardii in children 
with AGE has displayed therapeutic benefits, but more RCTs involving bigger sample sizes and with improved 
methodology is needed.40 
 
Based on these reporting’s, it is evident that therapeutic benefit from the use of Saccharomyces boulardii has 
the potential to be the sole or adjunct treatment in treating AGE.  Despite the results of the systematic reviews 
and studies discussed above being derived from mostly RCTs, the number of potential areas where confounding 
and bias is possible is far too many.  As a result, the aim of this research project is to provide a systematic up-to-
date review of published studies, specifically assessing the efficacy and safety of Saccharomyces boulardii on 
the treatment of AGE in the pediatric population. 
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CHAPTER 2 
METHODOLOGY 
 
2.1 INTRODUCTION 
Guidelines on the management of GE in the pediatric hospitalized patient are currently available.8-10  However, 
UNICEF still reports that GE remains a leading cause of death in children, i.e. GE was responsible for 9 percent 
of all deaths among children under-five in 2015.8-10  Although simple effective treatments are available, 1400 
children are still reported to be dying each day from this symptom.  The use of the yeast probiotic 
Saccharomyces boulardii has been researched as a possible treatment option for GE and for restoring gut 
microflora.25-33  The data generated by this research was systematically collated in this review.  This chapter 
serves to describe the following components required for the planning, and conducting of this systemic review: 
the purpose and objectives of this study, study design, study population, the method of data collection and 
analysis, and the piloting methods used. 
 
2.1.1 Purpose of the study 
The purpose of this systematic review was to assess the efficacy and safety of the yeast probiotic 
Saccharomyces boulardii in the treatment of AGE in the pediatric hospitalized population.  
 
2.1.2  Research Objectives 
2.1.2.1 Primary outcomes 
The primary objective of this systematic review was two-fold, i.e. to assess the overall efficacy of 
Saccharomyces boulardii on the duration of diarrhea in the pediatric patient admitted to a hospital 
setting with AGE; and to establish the safety of this yeast probiotic for use in the pediatric hospitalized 
patient. 
 
2.1.2.2 Secondary outcomes 
The secondary objectives of this systematic review were to assess how use of Saccharomyces boulardii 
as part of a treatment regimen impacted on the pediatric patients’ length of stay in hospital and therefore 
associated costs.   
 
2.1.2.3 Other outcomes 
Additional findings on optimal dosing, mode of delivery, frequency of treatment, duration of treatment 
and timing of delivery of this intervention were also investigated.   
 
2.2 CRITERIA FOR SELECTING STUDIES FOR THIS REVIEW 
2.2.1 Types of studies 
Only RCTs, involving human participants, investigating the efficacy and safety of Saccharomyces boulardii were 
considered for inclusion.  Trials were included regardless of the lack of blinding or placebo treatment.  All other 
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study designs (e.g. cross-over trials, quasi-controlled trials, case studies, observational studies, retrospective 
studies, non-randomized, non-controlled, expert opinion, and traditional reviews) were excluded. 
 
2.2.2 Types of participants 
Infants and pediatric patients, aged between 0 and 16 years, admitted to a hospital setting with a diagnosis of 
AGE (≥ 3 unformed stools in the last 24 hours and of ≤ 48 hour duration).  Studies including patients with the 
following characteristics were excluded from this review:  chronic illnesses, under-nutrition, severe dehydration, 
known allergies, recent history of use of one or a combination of probiotics, antibiotics and anti -diarrhea 
medication.   
 
2.2.3 Types of interventions 
Only studies using Saccharomyces boulardii as the intervention were included.  Any study, in which the 
Saccharomyces boulardii intervention was confounded by another intervention and without a proper control, was 
excluded.  Use of other strains of Saccharomyces (as the intervention) was not included.   
 
2.2.4 Types of outcome measures 
Outcome measures which required daily record keeping included the following: 
 Duration of diarrhea in days  
 Mean number of stools passed per day  
 Mean number of episodes of diarrhea at follow up 
 Frequency of diarrhea at start, mid-point and end of intervention 
 Stool frequency 
 Changes in stool consistency post intervention 
 Duration of hospital stay in days 
 
Modifiers and confounders included: 
 Active ingredients offered concurrently with the intervention (e.g. antibiotics) 
 The intervention being offered as part of a cocktail treatment  
 Differences in dosages offered and method of administration 
 
2.3  SEARCH METHODS FOR IDENTIFICATION OF STUDIES 
A comprehensive literature search of computerized databases was conducted with the guidance of a qualified 
Medical Librarian (Mrs. Wilhelmine Pool). Databases searched included: Medline (accessed via PubMed); 
EBSCO host (Elton B Stephen’s Company), including Academic Search Premier, Cumulative Index to Nursing 
and Allied Health Literature (CINAHL), Africa Wide and CAB Abstracts (produced by CABI Publishing, which 
covers the significant research and development literature in agriculture, forestry, human nutrition, veterinary 
medicine and the environment); Cochrane Library which includes the Cochrane Databases of Systematic 
Reviews (CDSR, Cochrane Reviews), Cochrane Central Register of Controlled Trials (CENTRAL; Clinical 
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Trials), Databases of Abstracts of Reviews of Effects (DARE; Other Reviews); ISI Web of Knowledge – Web of 
Science; Scopus (abstract and citation database of peer-reviewed literature); ProQuest Medical Library; Science 
Direct; and SABINET (South African Bibliographic Information Network).   
 
Additional literature was obtained through hand searching and reviewing of reference lists of articles and 
systematic reviews which appeared in the primary search.  Studies were selected regardless of language, 
publication date or status, with electronic searches commencing 10 April 2014 and ending 27 January 2015.  
 
The final search string used was: (probiotic OR Saccharomyces boulardii) AND (diarrh* OR gastroent*) AND 
(clinical trial* OR randomized control trial* OR random allocation OR placebo* OR random research OR 
comparative OR evaluation stud* OR follow up OR prospective* OR control* OR volunteer* OR single mask* OR 
double mask* OR treble mask* OR tripl* mask* OR double mask* OR treble mask* OR tripl* mask* OR single-
blind OR double-blind OR treble blind OR tripl* blind).  The only limits applied whilst using this search string was 
human and child (birth to 16 years), and therefore foreign language articles were included.  This search string 
was adapted where relevant and applied across all databases that were mentioned above. 
 
2.4  DATA COLLECTION AND ANALYSIS 
Preliminary screening was conducted by one reviewer (MP).  Articles that were clearly non-relevant to the 
current systematic review were filtered out of the search pool (e.g. multi-species trials, not related to AGE but 
rather inflammatory bowel disease, updates and commentaries).  Following this process, the screening steps 
that followed were completed independently and in duplicate by each of the two identified reviewers (MP and 
EV). 
 
2.4.1 Selection of studies 
Following removal of clearly non-relevant articles, two reviewers (MP and EV) independently screened the titles 
and abstracts of the articles identified by the search and applied the pre-defined inclusion criteria in order to 
identify eligible studies.  The form used to standardize this process was one t hat was adapted from the 
Cochrane Handbook, the “Study Eligibility Form” (see Appendix 6.1).  In the event of there being disagreement 
with the eligibility of a specific abstract for inclusion in this research review, the reviewers documented this and 
proceeded to obtain the full text article for further clarification.  Where the two reviewers were not able to achieve 
consensus on such a matter, a third opinion was sought from the primary research team.  Studies that initially 
appeared to be relevant but subsequently excluded are discussed in the section “Ex cluded studies”, together 
with the reasons for exclusion. 
 
2.4.2 Data extraction and management 
A Data Extraction Form (see Appendix 6.2) that was developed using the Cochrane Library resources was 
piloted using three of the full text articles that were identified as not applicable for placement in the list of 
included studies.  Following piloting, this standardized Data Extraction Form was then used by each of the two 
reviewers (MP and EV) to independently extract data from the full text articles used in this research review.   
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For each study, a review title/ID was assigned and the following information was recorded:  
 General information (i.e. surname of first author and year published; authors contact details; publication 
type; name of the reviewer completing the form; date on which the form was completed); 
 Methods (i.e. aim of the study; study design type; method of recruitment; inclusion and exclusion criteria; 
informed consent obtained; ethical approval needed/obtained; funding being clear to indicate both the 
source and amount; statistical methods used); 
 Participants (i.e. population description; setting; total number randomized; age; gender; ethnicity; 
baseline imbalances; withdrawals/exclusions; severity of illness; co-morbidities; other socio-
demographics; subgroups measured; subgroups reported);  
 Intervention group/s (i.e. group name; description; duration of treatment period; timing; delivery of 
intervention; providers; co-interventions; economic information; resource requirements);  
 Outcomes (i.e. outcome type; outcome name; time points measured; time points reported; outcome 
definition; person measuring/reporting; unit of measurement; imputation of missing data; assumed risk 
estimate; power); 
 Risk-of-bias assessment (i.e. random sequence generation; allocation concealment; blinding of 
participants and personnel; blinding of outcome assessment; incomplete outcome data; selective 
outcome reporting; other bias); 
 Data analysis (i.e. comparison; outcome; subgroup/s; time point; post-intervention or change from 
baseline; other results; number of missing participants; reason for missing; number of participants that 
moved groups and reason for the move; unit of analysis); and 
 Other information (i.e. key conclusions of study authors; relevant references). 
 
2.5  ASSESSMENT OF METHODOLOGICAL QUALITY OF INCLUDED STUDIES  
Each of the two reviewers independently assessed the components of each of the included studies for risk -of-
bias.  This was done by using a risk-of-bias tool (see Appendix 6.3), as described by the Cochrane Handbook for 
Systematic Review of Interventions (see Table 2.1).1  This tool helped to evaluate the potential sources of bias in 
the methodology of the included studies. The methodological domains of the studies were evaluated and 
classified as adequate, inadequate or unclear, as shown in Table 2.1 below.  More detail regarding how this 
evaluation was conducted will be discussed later. 
 
The domains of the methodology that were assessed are sequence generation, allocation concealment, blinding, 
incomplete outcome data, selective outcome reporting, and other potential sources to affect validity.1,2,38  
Assessment was done by answering a pre-specified question about the adequacy of the study in relation to the 
entry, in such a way that the judgment of ‘yes’ can be indicative of low risk -of-bias, ‘no’ can be indicative of high 
risk of bias, and ‘unclear’ can be indicative of uncertain risk of bias.1,2,38 Disagreements between each of the 
reviewers’ judgments were resolved by discussion, and consensus was reached in all cases.  
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“Summary of findings” tables were used to display the risk-of-bias for important outcomes within and across 
studies.  RCTs were considered high quality evidence, but were further extrapolated into limitations such as: 
risk-of-bias, consistency, directness, imprecision, and reporting bias. 
 
The GRADE system for rating overall quality of evidence for the most relevant outcomes was applied.  The 
quality of evidence was further categorized as either high (confident that the true effect lies close to that of the 
estimate of effect), moderate (moderately confident in the effect estimate), low (confidence in the effect estimate 
is limited) and very low (very little confidence in the effect estimate).38 
 
Table 2.1: The Cochrane Collaboration’s tool for assessing risk-of-bias
1
 
Domain Description Review Author’s Judgement 
Sequence 
generation 
Describe the method used to generate the allocation 
sequence in suff icient detail to allow  an assessment of 
w hether it should produce comparable groups. 
Was the allocation sequence adequately generated? 
Allocation 
concealment 
Describe the method used to conceal the allocation 
sequence in suff icient detail to determine w hether the 
intervention allocations could have been foreseen in 
advance of, or during enrolment. 
Was allocation adequately concealed? 
Blinding of 
participants, 
personnel and 
outcome 
assessors 
Describe all measures used to blind study personnel 
and participants from know ledge of which intervention 
relating to w hether the intended blinding w as effective. 
Was know ledge of the allocated intervention 
adequately prevented during the study? 
Incomplete 
outcome data 
Describe the completeness of outcome data for each 
main outcome, including attrition and exclusions from 
the analysis.  State w hether attrition and exclusions 
w ere reported, the numbers in each intervention group 
(compared to total randomized participants), reasons 
w ere reported, and any re-inclusions in analyses 
performed by the review authors. 
Were incomplete outcome data adequately addressed, 
regarding the amount, nature and handling of 
incomplete data? 
Selective outcome 
reporting 
State how  the possibility of selective outcome reporting 
w as examined by the review  authors, and what was 
found. 
Are reports or the study free of suggestion of selective 
outcome reporting? 
Other sources of 
bias 
State any important concerns about bias bot being 
addressed in the other domains of the tool. 
Was the study free of other problems, not covered 
elsew here in the table, making it high risk? 
 
2.6 MEASUREMENTS OF TREATMENT EFFECT 
2.6.1 Dichotomous data 
All dichotomous data resulted in the following information being extracted from each treatment group: the 
number of participants with the event and the total number of participants.  Risk ratios (RRs) were calculated for 
all dichotomous data. 
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2.6.2 Continuous data  
All continuous data resulted in the following information being extracted from each treatment group: the 
arithmetic mean, Standard Deviation (SD) and the number of participants.  The SD was calculated using the 
95% CI and MDs was calculated for continuous data where applicable. 
 
2.6.3 Incidence data 
As an outcome, the included studies did not report on the incidence of GE.  Therefore, incidence rate ratios are 
not applicable. 
 
2.6.4 Dealing with duplicate publications 
Owing to a comprehensive search across multiple electronic databases, duplications of the same references, but 
from different sources were encountered.  These references were double-checked to confirm duplication by 
reviewing the date of publication, and once this was confirmed, only one of these (duplicated) references was 
included.   
 
2.6.5 Assessment of heterogeneity   
Assessment of heterogeneity was achieved through the visual inspection of the forest plots.1,2  CIs were 
assessed and considered to have statistical heterogeneity if there was poor overlap of the results of individual 
studies.  A Chi2 test for heterogeneity (significance level P < 0.1) was conducted and the I2 statistic calculated. 
The following guidelines were used for the interpretation of the I2 values1,2:  
  0% to 40%: might not be important 
 30% to 60%: may represent moderate heterogeneity 
 50% to 90%: may represent substantial heterogeneity 
 75% to 100%: considerable heterogeneity 
The value of I2 depended on the magnitude and direction of the effects, as well as on the strength of evidence 
for heterogeneity (e.g. P < 0.1 from the Chi2 test, or a CI for I2).1,2 
 
2.6.6 Assessment of reporting bias 
Funnel plots are usually used to explore the possibility of small study bias.1,2  Different explanations are used to 
explain funnel plot asymmetry such as publication bias, the effect of different study sizes and poor study design.  
Tests for funnel plot asymmetry should only be used when there are a least 10 studies included in a meta-
analysis, as fewer studies would result in the power of the tests being too low to identify chance versus real 
asymmetry.1,2  Since we did not have a meta-analysis of ten or more studies, we did not construct a funnel plot 
to assess publication bias. 
 
2.6.7 Data synthesis and analyses  
Data were analyzed using Review Manage 5 (RevMan 2008) software.  A random effects model of meta-
analysis was used due to the presence of significant heterogeneity of treatment effects between studies.  When 
homogeneity was displayed, a fixed effects model was applied.  The Mantel-Haenszel method of meta-analysis 
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was applied for dichotomous outcomes and the Inverse-Variance method was applied for continuous outcomes.  
In the event of participants in included studies not receiving the assigned intervention as stipulated in the  
protocol, or being lost to follow-up, an ITT analysis was applied.  In the event of missing data, the primary 
authors for the relevant studies were contacted for additional information.  This was in done in the form of an 
email, providing the relevant study information and the data missing.   
 
See Appendix 6.4 for an example of the correspondence forwarded to primary authors of studies used.  As per 
the protocol, all uncertain findings that were not appropriate for inclusion in the pooled analyses were reported in 
the review.   
 
2.6.8 Unit of analysis 
During data analyses, the reviewers took into account at what level the randomization of study subjects took 
place. The reviewers also assessed the included studies to make sure that the number of observations  made in 
the analysis matched the number of “units” that were randomized in the study.  
 
2.6.9 Sub group analysis and investigations of heterogeneity 
If statistical heterogeneity was present (P < 0.1), potentially influential study characteristics were further 
investigated by conducting subgroup analyses.   
 
2.6.10  Sensitivity analysis 
The researchers planned to perform sensitivity analyses in the event of there being other influencers on study 
results. 
 
2.7 ETHICAL & LEGAL ASPECTS 
No ethical approval is required for a systematic review, as it is not a formal study requiring human participation.  
The Health Research Ethics Committee of Stellenbosch University was notified of the proposed systematic 
review and for record purposes, the project was registered (Ethics Number X14/07/012, see Ethics letter, 
Appendix 6.5). 
 
The protocol was also registered at the Prospective Register of Ongoing Systematic Reviews (PROSPERO), 
which is an international database of prospectively registered systematic reviews on health and social care.  The 
registration number for this systematic review is CRD42014009913 (see Appendix 6.6). 
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CHAPTER 3 
RESULTS 
 
3.1  DESCRIPTION OF STUDIES 
3.1.1 Results of the search 
The revised search string across multiple computerized databases yielded a large number of hits (>2200) 
resulting in the need for a preliminary screening.  The result of this step yielded 190 papers, with no additional 
references being added.  During the identification process, 10 papers were removed owing to duplication.  A 
further 68 papers were removed during the screening process for the following reasons: 13 were the wrong 
design or wrong setting; 4 carried out in the wrong population (adult/animal); 8 involved the concurrent use of 
other active treatments; 27 addressed non-acute GE; and 16 addressed causes other than Rotavirus.  The 
removal of a further 71 papers was necessary owing to the design being that of a systematic review.   
 
At this point, two independent reviewers (MP and EV) considered the remaining 41 papers for inclusion in this 
systematic review.  Of this pool, 7 were foreign language papers, of which 3 were written by the same author.  
Attempts at obtaining the English translations of these papers were made by contacting the relevant authors via 
email addresses found in each of the papers (see Appendix 6.4).  Only one of these authors responded stating 
that the papers were only available in French.  In addition, attempts at accessing translated versions of the 
respective articles via the Stellenbosch University library resources were also futile.  As a result, the research 
team took the decision to remove these references, citing this as one of the shortcomings of this systematic 
review.   
 
Full text articles for 25 of the 34 remaining eligible papers were obtainable.  The remaining 9 papers were 
removed from the steps that follow owing to the following reasons: 1 paper used the wrong study population; 1 
paper was a repetition of the foreign language paper that was not available in English; 7 papers were 
inaccessible.  Despite attempts by the Medical Librarian to access these remaining 7 papers, they were still 
found to be inaccessible owing to online versions starting after the date of public ation (see Appendix 6.4 for 
communication with research authors and the Medical Librarian).  The removal of these final 7 papers owing to 
inaccessibility would therefore be cited as a possible limitation of this systematic review, resulting in only 25 
papers advancing through to the study eligibility phase (see Figure 3.1 below). 
 
Whilst conducting independent assessments of these 25 studies, the two reviewers (MP and EV) agreed on a 
further 12 studies being removed: 1 study involved the concurrent use of other active ingredients, 2 studies were 
conducted in an outpatient setting, 2 were a wrong study type (e.g. in vivo), 2 were in the wrong study population 
(i.e. 18 to 60 years), and 5 addressed AGE caused by antibiotic therapy and not Rotavirus.  The remaining 
thirteen studies41-53 then advanced to the data extraction phase.  During this process, the 2 reviewers agreed on 
data extraction and inclusion of ten41,42,43,44,45,47,48,49,50,53 of the studies.  However, the remaining three studies 
were found to be inappropriate for inclusion: 2 studies46,52 included participants that were severely dehydrated, 
one study51 addressed GE caused by agents other than Rotavirus (see Figure 3.1 below for a summary of the 
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study selection process).  Therefore, only ten41,42,43,44,45,47,48,49,50,53 studies advanced to the next step of this 
systematic review, i.e. data analysis.   
 
3.1.2 Excluded studies 
Some of the main reasons for study exclusion were as follows: 71 took the form of a commentary, updates, 
guidelines, reviews and/or meta-analysis; 27 addressed GE that presented in forms other than acute; 16 
included a diagnosis other than Rotavirus-causing GE; 13 took place in a non-hospital setting; 10 were 
repetitions; 9 were not accessible either online or were not published; 8 involved the concurrent use of other 
active ingredients; 7 were references in a foreign language; and 4 involved inappropriate study participants.  The 
Table of Excluded Studies (Appendix 6.7) provides more information on the aforementioned references. 
 
3.1.3 Included studies 
Ten studies41,42,43,44,45,47,48,49,50,53 met the inclusion criteria and were included in this systematic review.  The ten 
included studies were published between the years 2006 and 2013.  Important information about these studies 
can be found in the “Characteristics of Included Studies” table (see Appendix 6.8).  A total of 1401 participants 
were included from the combined ten studies, with the smallest study 47 involving 27 participants and the largest 
study48 involving 480 participants.  All ten included studies were conducted in a hospital sett ing, but in multiple 
locations across the world i.e. 1 was conducted in Pakistan43, 2 conducted in India44,49, 1 conducted in Brazil45, 1 
conducted in Myanmar55, and 5 in different hospitals within Turkey41,42,47,48,50. 
 
All ten included studies adopted a study design that included both an intervention and control/placebo group, 
being monitored in parallel.  The intervention arm consisted of one or more interventions, but with 
Saccharomyces boulardii always being used as an independent intervention.  Across all ten studies, 
Saccharomyces boulardii was used at a dosage ranging from 200mg45 to 250mg41,43,44,47,48,49,50,53 with only one 
study42 offering the yeast probiotic at a slightly higher dosage of 282.5mg.  In terms of frequency of treatment, 50 
percent of the studies offered the intervention dose once42,44,45,48,50 per day and 50 percent offered the 
intervention dose twice per day41,43,47,49,53.   
 
Most studies41,44,45,48,49,50,53 considered the first five days as the “active" treatment days, with one study 43 using 
six days as the active treatment days.  Only one study 47 required the intervention to be implemented over a 
seven day period.  One study42 did not specify the minimum "active" treatment phase, but provided information 
on the mean duration-time of GE in all study groups of (5.9 ± 2.0) days.  Of all the included studies, only one43 
followed participants for two months post discharge to assess incidence of GE episodes post intervention. 
 
Not all included studies indicated or implemented the use of a placebo in their study designs, i.e. six 
studies41,42,43,44,48,53 did not describe or make use of a placebo, whilst the remaining four studies 45,47,49,50 
mentioned/described the placebo treatment used.   
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The four studies that described use of a placebo did so in different ways, i.e. one study 50 offered both the 
intervention and an identical-looking placebo diluted in water or juice (as advised by the manufacturer);  one 
study47 offered both the intervention and placebo dissolved in water; one study 49 offered both the intervention 
and placebo in identical packets mixed with puffed rice powder; and one study 45 offered both the intervention 
and placebo in capsule form, which were prepared by a faculty pharmacy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 PRISMA study flow diagram 
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3.2 RISK-OF-BIAS IN INCLUDED STUDIES 
By using the “Risk-of-Bias Tool” (see Appendix 6.3), the two reviewers (MP and EV) independently assessed 
each of the ten included studies for any risk-of-bias.  Six methodological quality domains were addressed, i.e. 
adequate sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting 
and other potential sources of bias.   
 
Appendix 6.9 summarizes the consensus-judgments reached for each of these ten studies, together with 
supporting comments.   
 
3.2.1 Adequate sequence generation 
Random sequence generation was adequate in four41,44,48,53 of the 10 studies (see Figure 3.2 and 3.3).  The 
remaining 6 studies42,43,45,47,49,50 did not clearly indicate how adequate sequence generation was achieved.  None 
of the studies led to the conclusion of being at high risk-of-bias in this domain. 
 
3.2.2 Allocation concealment 
Two45,49 of the ten studies clearly described how adequate allocation concealment was achieved (see Figure 3.2 
and 3.3).  Two41,43 studies posed a high risk-of-bias.  The remaining six studies42,44,47,48,50,53 did not clearly 
describe how this domain was achieved. 
  
3.2.3 Blinding 
The blinding of participants and personnel was found to be adequate in four45,47,49,50 of the ten studies.  
Three41,42,53 studies posed a high risk to blinding practices and the remaining three studies43,44,48 did not provide 
enough details to be totally clear about bias infringements in this domain (see Figure 3.2 and 3.3).  
 
3.2.4 Blinding of outcome assessment 
Fifty percent of the studies42,43,47,48,53 did not clearly indicate how blinding of outcome assessment was 
guaranteed.  The remaining studies consisted of only one study50 that did not provide for adequate blinding of 
this domain and four studies41,44,45,49 achieving adequate blinding (see Figure 3.2 and 3.3). 
 
3.2.5 Incomplete outcome data 
Six studies41,43,44,45,48,49 provided enough information to be considered adequate prevention of attrition bias.  The 
remaining four studies42,47,50,53 were assessed as unclear owing to insufficient details on how this  domain was 
achieved (see Figure 3.2 and 3.3). 
 
3.2.6 Selective outcome reporting 
Eight studies38,40,41,42,44,45,46,50 all clearly reported on all outcomes initially mentioned.  Only one study39 did not 
adequately accommodate for reporting bias.  One study47 did not provide sufficient information on all outcomes 
reported (see Figure 3.2 and 3.3). 
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3.2.7 Other potential sources of bias 
Sources of funding could possibly play a role as a potential source of bias.  Two of the included studies 43,47 were 
funded and supported by pharmaceutical companies, with one study47 declaring no conflict of interest in relation 
to the study.  One study44 acknowledged receiving financial support from a university affiliated with the hospital 
where the study was conducted.  Another study45 reported support from a government council involved with 
scientific and technological development.  Fifty percent of the included studies41,42,48-50 did not disclose any 
information about source of funding or financial support received.  However, one of these studies 49 made a 
simple declaration that no conflict of interest and no funding were received for the study.  The one remaining 
study53 was the only study where authors commented that it was completed with a very limited budget owing to 
there being no involvement of the company commercializing the yeast probiotic that was used in the 
interventional arm. 
 
Other areas of bias did not appear to be a concern in eight of the included studies41,42,43,45,47,49,50,53 and was 
considered adequate.  Only two studies44,48 provided insufficient information making it challenging to remove 
other sources of bias from their study designs (see Figure 3.2 and 3.3). 
  
 
Figure 3.2: Methodological quality summary: judgments about each methodological quality item for each 
included study (10) 
Key: 
 
(+) Indicates adequate  
 
(?) Indicates unclear 
 
(-) Indicates inadequate 
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Figure 3.3: Methodological quality graph: judgments about each methodological quality item presented 
as percentages for all included studies (n=10) 
 
3.3 METHODOLOGICAL QUALITY OF GROUPS OF STUDIES 
The methodological quality of the included studies was then assessed using the GRADE tool.  Using GRADE-
pro software, the following, most relevant outcomes were assessed for overall methodological quality: duration 
of diarrhea, mean number of stools per day, frequency of diarrhea, number having less than three stools per day 
and duration of hospital stay.  A summary of findings table was generated (see Table 3.1 below).   
 
The first outcome for which methodological quality was assessed was that of “duration of diarrhea (in days).  
Five studies42,44,48,49,50 were pooled in a random effects meta-analysis, resulting in a total sample population of 
548 participants.  The quality of evidence was downgraded (-1) owing to 4 studies42,44,48,50 showing increased 
risk-of-bias owing to a combination of selection bias42,44,48,50, performance bias42,44,48, detection bias42,48, attrition 
bias42,reporting bias50 and other bias48.  However, there was no downgrading for inconsistency as 4 of the 5 
included studies displayed no heterogeneity (I2 = 0%) and CIs overlapped, indicating that any variation in the 
size of effect was more likely as a result of chance.  Overall, this outcome produced a quality assessment that 
was rated moderate. 
  
The second outcome assessed for standard of quality was “mean number of stools per day”.  This  outcome 
consisted of only 1 study47 and the overall quality of this study was found to be low owing to the following 
reasons: (-1) for risk-of-bias as both selection bias (no detail of how randomization and allocation concealment 
were achieved) and detection bias (no detail on the outcome assessment technique used) were present.  In 
addition, downgrading (-1) for inconsistency was applied as only Day 0 out of the five days intercepted the line of 
no effect meaning that any variation in the size effect is not due to chance (I2 = 95.3%, P = < 0.00001). 
 
The study45 investigating frequency of diarrhea being less than three times per day was found to display an 
overall quality rating of high.  The reasons for this are as follows: this was a well -controlled study which 
displayed zero risk of bias, downgrading (-1) was applied owing to inconsistency as heterogeneity was present 
(I2 = 96%, P < 0.00001), and only one day (Day 1) of the study overlapped the line of no effect. This quality of 
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this study’s
45 evidence was upgraded as it produced a RR of 0.66, indicating that the Saccharomyces boulardii 
were more likely to experience fewer stools per day versus the control group.  
 
The quality assessment for a study53 consisting of an overall sample pool of 700 participants was found to be 
moderate for assessing the number of participants passing less than three stools per day during the first seven 
days after starting intervention.  Overall, (-1) was applied for risk-of-bias as both performance and detection bias 
were noted.  In addition, (-1) was applied for inconsistency as the forest plot completed indicated non-
overlapping CIs, high I2 (95%) and an accompanying low P value (< 0.00001).  However, upgrading of the 
quality of this evidence was applied as a RR (1.13) was indicative of the Saccharomyces boulardii  group being 
1.13 times more likely to experience less than three stools per day quicker than the control group.  
 
The final test for methodological quality involved two studies48,50 which investigated the effect of use of this yeast 
probiotic on length of stay on hospital.  Despite the two studies producing a pooled sample study population of 
320 participants, the quality of the evidence was found to be low owing to the following: (-1) for risk-of-bias in 
areas of selection bias48, reporting bias48.  In addition, this particular study48 was also concerning as of the 480 
participants originally recruited, these authors reported that all 480 of them completed the study, with no 
withdrawals, exclusions of loss-to-follow-up.  In addition, (-1) for inconsistency was applied (variation in size of 
effect likely no due to chance, high heterogeneity with I2 = 95%, and very low P value of < 0.0001). 
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Table 3.1: Summary of findings table using GRADE - Saccharomyces boulardii compared to Control or Placebo for AGE 
Patient or population: patients with AGE 
Settings: in pediatric, hospitalized patients 
Intervention: Saccharomyces boulardii 
Comparison: Control or Placebo  
Outcomes Illustrative comparative risks* (95% CI) Relative effect 
(95% CI) 
No of Participants 
(studies) 
Quality of the 
evidence 
(GRADE) 
Comments 
Assumed risk Corresponding risk 
 
Control or 
Placebo 
Saccharomyces boulardii 
    
Duration of diarrhea 
measured in days 
Follow -up: mean 5-7 days 
 The mean duration of diarrhea in the intervention groups 
w as 
0.57 lower 
(0.83 to 0.3 low er) 
 548 
(5 studies) 
⊕⊕⊕⊝ 
moderate1,2 
 
Mean number of stools per day 
number of stools per day 
Follow -up: mean 7 days 
 The mean number of stools per day in the intervention 
groups w as 
0.97 lower 
(1.56 to 0.39 low er) 
 133 
(1 study) 
⊕⊕⊝⊝ 
low 3 
 
Frequency of diarrhea 
Evacuation frequency was <3 times 
per day 
Follow -up: mean 5 days 
Study population RR 0.66  
(0.35 to 1.23) 
528 
(1 study) 
⊕⊕⊕⊕ 
high4,5,6 
 
775 per 1000 512 per 1000 
(271 to 953) 
Moderate 
802 per 1000 529 per 1000 
(281 to 986) 
Number having <3 stools per day 
stools passed 
Follow -up: mean 7 days 
Study population RR 1.13  
(0.97 to 1.31) 
700 
(1 study) 
⊕⊕⊕⊝ 
moderate7,8 
 
657 per 1000 743 per 1000 
(637 to 861) 
Moderate 
780 per 1000 881 per 1000 
(757 to 1000) 
Duration of hospital stay (days) 
in days 
 The mean duration of hospital stay (days) in the 
intervention groups w as 
0.12 lower 
(1.9 low er to 1.65 higher) 
 320 
(2 studies) 
⊕⊕⊝⊝ 
low 9,10,11 
 
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.  The corresponding risk (and its 95% confidence interval) is based on the 
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio 
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GRADE Working Group grades of evidence: 
High quality: Further research is very unlikely to change our confidence in the estimate of effect.  
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
1 SELECTION BIAS (Kurugol 2005, Erdogan 2012, Burande 2013, Dalgic 2011); REPORTING BIAS (Kurugol 2005, Erdogan 2012); BLINDING (Erdogan 2012, Burande 2013, Dalgic 2011); 
OTHER BIAS (Dalgic 2011, Riaz 2013).   
2 No dow ngrading for inconsistency as: 4 of 5 studies have CIs that overlap meaning that any variation in the size of effect is  more likely a result of chance; I2 value of 0% indicating no 
heterogeneity; non-signif icant P-value. 
3 Dow ngrading for inconsistency as only Day 0 out of 5 days intercepted the line of no effect meaning that any variation in the size of effect is not due to chance; I2 value is very high 95.3% 
indicating heterogeneity; very low  P value (<0.00001). 
4 Dow ngrading for inconsistency as the forest plot for this outcome show s that of each of the 3 days of assessment, only results for Day 1 overlap w ith the line of no effect; the overall test for 
heterogeneity show ed a high I2 of 96% and a very low  P value (<0.00001). 
5 No dow ngrading as this outcome show s a w ide CI w ith the effect on the side favoring benefit, a large number of events (148+200) and a large sample size (270+258). 
6 Corrêa 2011: A RR of 0.66 indicating that the Saccharomyces boulardii group was 34% more likely to experience fewer stools per day versus the control group. 
7 Htw e 2008: not all CIs overlap the line of no effect; I2 value quite high at 95% and accompanied by a very low  P value (<0.00001). 
8 Htw e 2008: Overall, this analysis showed a RR (1.13) indicating that the Saccharomyces boulardii group was 1.13 times more likely to experience <3 stools per day quicker than the control 
group.  
9 Only Dalgic 2011 and Kurugol 2005 assessed impact of Saccharomyces boulardii on length of hospital stay. 
10 Dalgic 2011: SELECTION BIAS w as unclear as no information w as given on how  allocation concealment w as achieved. REPORTING BIA S as no mention is made regarding the training of 
parents for reporting of symptoms like "appearance of stools", "w atery GE", "GE". OTHER BIAS: 480 participants w ere recruited and all 480 w ere reported to have completed the study, w ith no 
w ithdrawals, exclusions or loss to follow-up? 
11 Dow ngrading for inconsistency as neither study truly overlaps with the line of no effect meaning that any variation in the size of effect is not due to chance; I2 value is very high 95% indicating 
heterogeneity; very low  P value (<0.0001). 
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3.4 EFFECTS OF INTERVENTION 
All ten of the included studies investigated the effects of Saccharomyces boulardii on AGE, but in two different 
comparisons, i.e. nine of the studies42,43,44,45,47,48,49,50,53 compared Saccharomyces boulardii against a control or 
placebo, whilst one study41 compared Saccharomyces boulardii against a yoghurt fluid containing Lactobacillus 
bulgaricus and Streptococcus thermophiles.   
 
One study48 evaluated Saccharomyces boulardii versus the following multiple comparisons: zinc; lactose-free 
formula; (Saccharomyces boulardii + zinc); (Saccharomyces boulardii + lactose-free formula); (zinc + lactose-
free formula); (Saccharomyces boulardii + zinc + lactose-free formula); (ORS alone).  In order to avoid the unit of 
analysis error due to multiple comparisons, a one pair-wise comparison was used for analysis, i.e. group 7 
(Saccharomyces boulardii + zinc + lactose-free formula) versus group 6 (zinc + lactose-free formula). This was 
included in first comparison because it was assessing Saccharomyces boulardii versus control.   
 
3.4.1 Comparison group: Saccharomyces boulardii versus control or placebo 
Nine studies evaluated Saccharomyces boulardii versus control42,43,44,48,53 or placebo45,47,49,50 group.  These were 
analyzed together since there were no active ingredients in either the control or the placebo.  
 
3.4.1.1 Primary outcomes 
All of the included studies investigated the efficacy of Saccharomyces boulardii on GE caused by Rotavirus, but 
reported their findings in somewhat different ways.  Seven studies42,43,44,48,49,50,53 reported duration of diarrhea (in 
days).  One study44 reported the outcome as recovery from loose motions. Five studies42,44,48,49,50 were pooled in 
a random effects meta-analysis which showed that Saccharomyces boulardii significantly shortened the duration 
of diarrhea (in days), compared to the control or placebo group (MD -0.57; 95% CI: -0.83 to -0.30; n=548 
children; 5 studies).  Furthermore, there was no significant heterogeneity detected between the trials (Tau2=0.00; 
Chi2=1.57; df=4; P=0.81; I2=0%) (see Figure 3.4 below). 
 
 
Figure 3.4: Forest plot: difference in duration of diarrhea (in days; Saccharomyces boulardii versus 
control) 
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Although two studies43,53 reported the mean duration of diarrhea without the corresponding SDs, and therefore 
could not be included in the above meta-analysis, the study authors reported that Saccharomyces boulardii 
significantly shortened the duration of diarrhea (in days), compared to the control group in both studies, i.e. one 
study43 (MD -1.2 (3.6 versus 4.8); n=100 children; 1 study; P = 0.001); and one study53 (MD -1.6 (3.08 versus 
4.68); n=100 children; 1 study; P < 0.05). 
 
Another three studies43,47,49 reported on the mean number of stools per day, with one study49 also reporting the 
mean number of stools per day for 0 to 24 hours, 25 to 48 hours, and 49 to 72 hours. However, the results of the 
latter study were skewed (mean <2 SDs) and therefore no meta-analysis could be done.  Although the other 
study43 reported the mean number of stools per day, no corresponding SDs were reported, rendering it 
unsuitable for inclusion in the meta-analysis.  These authors43 however, did report that use of Saccharomyces 
boulardii offered statistically significant effects on the number of stools per day compared to the control group for 
Day 3 (MD -1.6 (2.8 versus 4.4); P = 0.01) and Day 6 (MD -1.7 (1.6 versus 3.3); P = 0.001), but not for Day 0 
(MD (9.5 versus 8.8); P = 0.37).  Results from the remaining study47 showed a significant difference in the mean 
number of stool per day between the Saccharomyces boulardii group and the control group for Day 1 (MD -0.86; 
95% CI: -1.15 to -0.57), Day 2 (MD -1.21; 95% CI: -1.49 to -0.93), Day 3 (MD -1.68; 95% CI: -1.93 to -1.43) and 
Day 4 (MD -1.38; 95% CI: -1.65 to -1.11), but there was no difference on Day 0 (MD 0.31, 95% CI: -0.06 to 
0.68).  Overall, the pooled effect size for the duration of treatment of AGE in this study favored the 
Saccharomyces boulardii group (P = 0.001) (see Appendix 6.10). 
 
Only one study43 reported on the mean number of episodes of diarrhea after Month 1 and Month 2 but there 
were no SDs reported. Even though the CIs for the MD between the Saccharomyces boulardii and control 
groups could not be calculated, the authors43 reported that Saccharomyces boulardii significantly shortened the 
mean number of episodes of diarrhea compared to the control group for both Month 1 (MD -0.44 (0.2 versus 
0.64); n=100 children; P = 0.001) and Month 2 (MD -0.24 (0.32 versus 0.56); n=100 children; P = 0.04). 
 
One study45 reported the number of children having diarrhea at each day after starting the intervention and the 
results show that Saccharomyces boulardii significantly reduced the risk of diarrhea compared to the control 
group for Day 2 (RR 0.54; 95% CI: 0.42 to 0.70; n=176 children) and Day 3 (RR 0.54; 95% CI: 0.38 to 0.77; 
n=176 children) but not on Day 1 (RR 0.96; 95% CI: 0.87 to 1.05; n=176 children).  Overall, the effect of 
Saccharomyces boulardii for the first three days of treatment did not demonstrate superiority over the control, 
producing a non-significant result (P = 0.19) (see Appendix 6.11). 
 
One study53 reported on the number of children having less than 3 stools per day after starting the intervention 
and the results show that significantly more children were having less than three stools per day in the 
Saccharomyces boulardii group (n=50) compared to the control group (n=50) on Day 2 (RR 1.80; 95% CI: 1.10 
to 2.95), Day 3 (RR 1.39; 95% CI: 1.05 to 1.85), and Day 4 (RR 1.23; 95% CI: 1.05 to 1.44). On Day 1, none of 
the children had less than three stools per day in both groups. On Day 6 and Day 7, all the children had less 
than three stools per day. On Day 5, there was no difference in the number of children having less than three 
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stools per day in the two groups (RR 1.04; 95% CI: 0.97 to 1.11).  Although this analysis appeared to moderately 
favor the Saccharomyces boulardii group, it was not statistically significant (P = 0.11) (see Appendix 6.12). 
 
One study53 reported on the number of children having solid stools per day, after starting intervention and the 
results show that significantly more children were having solid stools in the Saccharomyces boulardii group 
(n=50) compared to the control group (n=50) on Day 2 (RR 3.00; 95% CI: 0.32 to 27.87), Day 3 (RR 3.17; 95% 
CI: 1.89 to 5.31), Day 4 (RR 1.63; 95% CI: 1.30 to 2.06) and Day 5 (RR 1.25; 95% CI: 1.08 to 1.44). On Day 1, 
none of the children had solid stools in both groups. On Day 7, all the children had solid stools. On Day 6, there 
was no difference in the number of children having solid stools between the two groups (RR 1.04; 95% CI: 0.97 
to 1.11).  Although the results appeared to favor the Saccharomyces boulardii group, it was not statistically 
significant (P = 0.06) (see Appendix 6.13). 
 
In addition to the above, one other primary outcome of the current systematic review was to investigate the 
safety of use of this yeast probiotic in the pediatric hospitalized patient.  None of the included studies reported on 
any significant side effects associated with Saccharomyces boulardii use.   
 
3.4.1.2 Secondary and other outcomes 
Two studies48,50 reported on the duration of hospital stay (in days) and their results were combined in a meta-
analysis that resulted in significant statistical heterogeneity (Tau2=1.55; Chi2=18.94; df=1; P < 0.0001; I2=95%). 
Therefore, their results are reported separately: the first study48 found a longer duration of hospital stay in the 
Saccharomyces boulardii group (MD 0.81; 95% CI: 0.09 to 1.53; n=120 children) compared to the control group.  
However, the second study50 showed that Saccharomyces boulardii significantly shortened the duration of 
hospital stay, in days, compared to the placebo group (MD -1.00; 95% CI: -1.38 to -0.62; n=200 children) (see 
Figure 3.5 below). 
 
 
Figure 3.5: Forest plot: duration of hospital stay (in days, Saccharomyces boulardii versus control) 
 
None of the ten studies evaluated other outcomes (e.g. cost-effectiveness, optimal dosing and delivery method, 
frequency/duration of treatment, timing of delivery of Saccharomyces boulardii). 
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3.4.2 Comparison group: Saccharomyces boulardii versus yoghurt fluid containing Lactobacillus 
bulgaricus and Streptococcus thermophiles 
Results for the above comparison41 were found to be non-significant for both the primary outcomes (i.e. duration 
of diarrhea in days was not different between the two groups: MD -0.93, 95% CI: -2.26 to 0.40; resolution of 
diarrhea at Day 3 and Day 5 showed that diarrhea had resolved significantly more in children in the 
Saccharomyces boulardii group on Day 3: MD 2.06, 95% CI: 1.02 to 4.15, but with no difference on Day 5 and 
an overall non-significant result of P = 0.26; and daily stool frequency reduction between the two groups yielded 
no significant difference: MD 0.96, 95% CI: -0.72 to 2.64) and secondary outcomes and therefore not discussed 
any further.41 
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CHAPTER 4 
DISCUSSION 
 
4.1 OVERALL COMPLETENESS AND APPLICABILITY OF EVIDENCE 
Any factor that disrupts the bowels multifaceted ecosystem can result in the development of gastrointestinal 
disease, with GE being one of the most documented symptoms.  The difficulty this presents is that GE can be 
categorized in various ways, i.e. according to cause (e.g. bacterial, viral, parasitic)4,7-10, or by severity (e.g. mild, 
moderate and severe).4,7-10  This systematic review was very specific as it aimed to include only those studies 
addressing mild-moderate GE caused by the Rotavirus.  In addition, subjects needed to be between 0 and 16 
years, be in a generally healthy condition with no other comorbidities, and qualify for hospitalization.  The 
addition of studies investigating the effects of Saccharomyces boulardii only made this a very challenging search 
for supporting studies.  Owing to these specifications, the initial search strategy was amended s o as to be as 
inclusive as possible.  This resulted in reviewers identifying ten RCTs involving a combined 1401 participants 
between the ages of 0 and 16 years for inclusion in this systematic review.  
 
The study settings within which each of the included studies took place were in many different countries across 
the globe (i.e. Pakistan, India, Brazil, Myanmar, and Turkey).  Aside from varied geographical settings, the 
included studies also included participants that were from varied backgrounds, socio-economic status’s, with 
different research resources, different research teams and therefore varied methodological quality standards.     
 
One of the secondary outcomes of the current systematic review was to investigate the effect of Saccharomyces 
boulardii on the days of hospitalization.  Of the ten included studies, only three studies 41,48,50 reported on this 
outcome and each with a different result.   
 
4.2 SUMMARY OF MAIN RESULTS 
The objective of this systematic review was to assess the effectiveness and safety of Saccharomyces boulardii 
in the management of AGE in the pediatric hospitalized population.  A comprehensive electronic search of 
potential studies, without language restrictions was carried out and resulted in ten studies (involving 1401 
participants) being included in this systematic review.  The included studies all considered Saccharomyces 
boulardii administration to pediatric patients being diagnosed with GE that was defined by WHO4 as ≥ three 
loose/watery stools in a 24 hour period, but without display of severe dehydration.  The quality of the individual 
included studies ranged between low and moderate, with unclear risk-of-bias displayed for especially the first 
four domains i.e. random sequence generation, allocation concealment, blinding of participants/personnel and 
blinding of outcome assessment (see Figure 3.2 and 3.3).  Some of the results for some outcomes showed clear 
differences between groups within single studies.  However, the manner in which outcomes were reported (i.e. 
number of stools per day, days to < three stools per day, mean number of stools) resulted in only one meta-
analysis being done. 
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4.2.1 Primary outcomes 
Five studies42,43,44,48,53 compared Saccharomyces boulardii with a control, while four studies45,47,49,50 compared 
Saccharomyces boulardii with a placebo.  No active ingredients were present in either the control or placebo, 
thereby presenting no risk of any confounding effects.  However, only five studies 42,44,48,49,50 reported the primary 
outcome of duration of GE in days and were therefore included in the first meta-analysis (Figure 3.4).  Of these 
five studies42,44,48,49,50, a total sample size of 274 participants was achieved and of the five studies, three44,49,50 
showed individual statistical significance not intercepting the line of no effect and therefore favoring the use of 
Saccharomyces boulardii.  Overall, the participants in the Saccharomyces boulardii group produced a 
statistically significant result (P < 0.0001) indicating that participants exposed to the Saccharomyces boulardii 
intervention experienced a shorter duration of GE (MD -0.57; 95% CI: -0.83 to -0.30) than the control/placebo 
groups.  These findings would have been more robust had a larger number of studies of similar design and 
investigating similar outcomes were available. 
 
Analyzing data from the remaining four studies43,45,47,49 was not straight-forward, as one study45 reported findings 
as frequency of GE after three days of starting the Saccharomyces boulardii intervention, whilst the remaining 
three studies43,47,49 reported on the “mean number of stools per day”.  Data provided by two of the studies 43,49 
could not be combined in a meta-analysis with data from the remaining study47, i.e. one study49 produced 
skewed results ( mean <2 SDs) resulting in it not being possible to calculate treatment effects ; and the other 
study43 reported the mean number of stools per day without corresponding SDs.  Analysis of data produced by 
the remaining study47 revealed changes in GE episodes from inclusion day (Day 0) up to and including Day 4.  
No difference in treatment effects were noted on Day 0, but this was not the case for ot her specified days.  
Results for this outcome showed that there was a significant difference in the mean number of stools per day 
between the Saccharomyces boulardii and the control group for Day 1 (MD -0.86; 95% CI: -1.15 to -0.57), Day 2 
(MD -1.21; 95% CI: -1.49 to -0.93), Day 3 (MD -1.68; 95% CI: -1.93 to -1.43) and Day 4 (MD -1.38; 95% CI: -
1.65 to -1.11).   
 
Although the study by Corrëa et al45 was aiming to assess the frequency of GE during the first three days after 
starting the Saccharomyces boulardii intervention, it is interesting that these researchers also found no notable 
difference between each of the groups on Day 0, but there were statistically significant reductions in the 
frequency of a loose stool being experienced on intervention Day 2 (RR 0.54; 95% CI: 0.42 to 0.70; P < 
0.00001) and Day 3 (RR 0.54; 95% CI: 0.38 to 0.77).   
 
The study by Riaz et al49 provided further support to these findings with the post-intervention GE between the 
Saccharomyces boulardii group (52.85 ± 24.6 hours) being significantly less than the placebo group (64.61 ± 
30.9 hours).  In addition, significance was found with the time of appearance of the first semi-formed stool in the 
Saccharomyces boulardii group (39.48 ± 23.09 hours) versus the placebo group (54.13 ± 28.21 hours).  
However, the results from each of these studies45,49 did differ in terms of the test for overall effect as Corrëa et 
al
45 found no statistical significance supporting the use of Saccharomyces boulardii in the management of AGE 
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whereas Riaz et al49 found favor in the Saccharomyces boulardii group (MD -0.97; 95% CI: -1.56 to -0.39; P = 
0.001).   
 
The objective of this systematic review was to assess the efficacy of Saccharomyces boulardii on AGE in 
pediatric patients that were admitted for management to a hospital setting.  As a result, post discharge 
assessments were not supposed to be tracked.  However, one study 43 did assess episodes of diarrhea for 
participants post discharge, at both Month 1 and Month 2.  It was interesting to find that these authors43 found a 
residual treatment effect of Saccharomyces boulardii in the interventional arm, with a significantly short mean 
number of episodes of GE compared to the control arm, at both Month 1 (P = 0.001) and Month 2 (P = 0.04) 
follow-ups.  This study43 is the first one to report on the reduction in number of GE episodes during the post -
treatment follow-up period.  This finding is in support of reports by earlier papers13-15 that this yeast probiotic has 
a mechanism of action which stimulates the host’s immunity and enhances the trophic activity of mucosa by 
releasing polyamines, which contributes to its long-term activity of reestablishing normal microbiota status. 
 
The study carried out by Htwe et al53 chose to assess the number of participants passing fewer than three stools 
per day following commencement on the seven-day intervention study.  Similar to results reported by other 
studies43,45, no difference was recorded between the two groups in the first 24 hours.  However, like results 
reported by three other studies41,45,47, significant differences in stool frequency was recorded for Day 2, Day 3 
and Day 4 of the study, i.e. the Saccharomyces boulardii group was 1.80 times on Day 2 (95% CI: 1.10 to 2.95, 
P = 0.02), 1.39 times on Day 3 (95% CI: 1.05 to 1.85, P = 0.02) and 1.23 times on Day 4 (95% CI: 1.05 to 1.44, 
P = 0.01) more likely to experience less than three stools per day than the control group.  Little/no difference in 
stool frequency was noted between the two groups for Day 5, Day 6 and Day 7.  Although not found to be 
statistically significant (P = 0.11), the overall effect of this study was more in favor of the Saccharomyces 
boulardii group. 
 
The study by Htwe et al53 also aimed to report on the effects of Saccharomyces boulardii on the consistency of 
stool being passed over the study period.  The RR for Day 3, Day 4, and Day 5 were in favor of the 
Saccharomyces boulardii intervention group as these participants were more likely to pass solid stools as 
compared to the control group, i.e. Day 3 (RR 3.17; 95% CI: 1.89 to 5.31; P < 0.0001), Day 4 (RR 1.63; 95% CI: 
1.30 to 2.06; P < 0.0001), and Day 5 (RR 1.25; 95% CI: 1.08 to 1.44; P < 0.002). Although not a strongly 
statistically significant result (P = 0.06), the overall effect of offering Saccharomyces boulardii to pediatric 
subjects with AGE was found to offer an advantage as these subjects were 1.41 times more likely to pass a solid 
stool sooner than the control group subjects.  It must be noted though that the manner in which the “stool 
consistency” was assessed is questionable, i.e. according to these authors, information about the changes in 
stool consistency was assessed/recorded by the subjects mother or attendant.   Although these authors53 
provided specific definitions for the outcomes in their study, they failed to report on any parent/personnel training 
or on the use of standardized stool-assessment tool/s that were used to train the mothers and/or attendants.   
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Safety of use of the yeast probiotic was the other primary outcome under investigation, and of the ten included 
studies, only one study50 reported of a single participant complaining of “meteorism” which is defined as excess 
gas accumulating in the gastrointestinal system and causing abdominal distension.3  No additional information 
was provided by the authors and neither was there mention of the participant needing to be removed from the 
trial.  Other than this reporting, no serious adverse reaction in the Saccharomyces boulardii group were 
registered during any of the included studies. 
 
4.2.2 Secondary outcomes 
Duration of hospital stay will have both clinical and economic implications.  In this systematic review, three 
studies41,48,50 reported on the duration of hospital stay (in days).  Treatment groups for two studies 48,50 were 
comparable and their results were combined.  However, owing to significant heterogeneity (I2 = 95%), each of 
their results were reported separately.  The one study48 reported that the Saccharomyces boulardii group was 
found to have a longer stay in hospital as compared to the control group (MD 0.81, 95% CI: 0.09 to 1.53).  In 
direct contrast, the second study50 reported that the use of Saccharomyces boulardii resulted in a statistically 
significant (P < 0.001) impact on duration of stay in hospital (MD -1.00, 95% CI: -1.38 to -0.62), i.e. 
Saccharomyces boulardii group (2.9 days) versus the placebo group (3.9 days).  The remaining third study41 
found no significant difference in number of days spent in hospital between the Saccharomyces boulardii group 
and the yoghurt fluid group (MD 0.45; 95% CI: -0.64 to 1.54; P = 0.42). 
 
4.3 QUALITY OF EVIDENCE 
The ten studies included in this review lacked meticulousness when it came to methodological quality.  All ten 
trials met the prerequisite of being RCTs.  When judgment about each methodological quality item for each 
included study was performed, shortcomings across some of the domains for some of the studies were noted.  
Selection bias was clearly prevented in four studies41,44,48,53 as methods at simple randomization were described 
i.e. computer-generated random numbers44,48, according to identification numbers41 and simple alternated 
allocation to treatment and control groups.53  The remaining six studies42,43,45,47,49,50 reported carrying out 
randomization but details on how this was achieved were unclear.  
 
The manner in which allocation concealment was achieved was unclear in six studies42,44,47,48,50,53, while two 
studies45,49 adequately reported on this domain.  The remaining two studies41,43 did not report/describe the use of 
a placebo. 
 
Four of the studies45,47,49,50 adequately reported on controlling for performance bias by providing detailed 
information on the identical appearance of placebos offered.  Three of the studies 43,44,48 did not describe how 
personnel and participants were blinded from treatment options and therefore designated an unclear risk status.  
The remaining three studies failed at preventing performance bias as one study 41 was an open clinical trial and 
therefore both participants and personnel were not oblivious to allocated treatment options. Both Htwe et al53 
and Erdogan et al42 made no mention of any placebo being offered to control group participants.  
 
Stellenbosch University  https://scholar.sun.ac.za
 51 
 
Four studies41,44,45,49 were found to have low risk for detection bias, while five other studies42,43,47,48,53 provided 
insufficient information and were therefore categorized as unclear.  The study by Kurugol et al50 was found to be 
of high detection bias as a subjective method of reporting symptoms was described, i.e. parents of participants 
were contacted by the research team to gather data on stool numbers and consistency.  These authors50 did not 
describe any training offered to the parents, nor was a standard assessment tool used to categorize the quality 
and quantity of stools being passed.  In addition, no standard descriptions of different GE types were stipulated 
in this study’s50 methodology e.g. watery GE versus GE. 
 
The bulk of the studies41,43,44,45,48,49 were found to achieve low attrition bias status.  The remaining four 
studies42,47,50,53 did not provide sufficient detail on how this domain was addressed and therefore marked as 
unclear risk.   
 
All the studies41,43,44,45,47,48,49,53 except for two42,50 fully reported on all outcomes described at the onset.  
However, the reporting of results in the study by Kurugol et al50 was unclear as, although data was provided in a 
table format, the authors failed to describe in detail their observations of duration of watery GE, vomiting, fever 
and length of hospital stay.  The remaining study by Erdogan et al42 was identified as high risk for reporting bias 
as all outcomes except for stool consistency were reported on.  It must also be borne in mind that even though 
declared, one study43 did receive support and funding from a pharmaceutical company i.e. this company 
supplied the yeast probiotic preparation which was used in the Saccharomyces boulardii group.   
 
Overall, except for two studies44,48 with unclear risk of other biases, the studies included in this systematic review 
did not display other forms of bias. 
 
In order to assess the methodological quality of the included studies, a GRADE assessment was conducted (see 
Table 3.1).  Of all the outcomes analyzed, five of the most relevant were investigated further, i.e. duration of 
diarrhea, mean number of stools per day, frequency of diarrhea, number having less than 3 stools per day and 
duration of hospital stay.  Despite the absence of high quality evidence and uncertain values/preferences being 
presented, the overall quality of evidence across all critical outcomes was found to be moderate.  
 
4.4 POTENTIAL BIASES IN OVERVIEW PROCESS 
One of the biggest “threats” to systematic reviews is publication bias, defined as “the publication or non-
publication of research findings, depending on the nature and direction of results”.1,2  As a result, this would 
impact on the “true” nature of the research topic under investigation.  This systematic review is no exception as 
there is always the possibility that applicable research papers could have been missed or overlooked during 
various stages of the search and selection process.  The use of two reviewers (MP and EV), independently 
assessing studies for inclusion in this systematic review would have helped to address this form of bias, but is 
not 100 percent full-proof.   
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In addition, the final search strategy did not apply any language restrictions and yielded nine foreign language 
abstracts, of which one appeared to be a study that required full-text reviewing.  However, owing to the 
inaccessibility of the translated version of this article, the research team took to the decision to remove this study 
from the “included studies” category. 
 
Even though two reviewers (MP and EV) independently carried out study selection, data extraction/analysis and 
quality assessments, these all remain subjective judgments. 
 
4.5 AGREEMENTS AND DISAGREEMENTS WITH OTHER REVIEWS 
Like the current systematic review, other researchers like Szajewska et al (2007)33, McFarland (2010)29, Allen et 
al (2010)15 and Pan et al (2012)40 have attempted to review and possibly put forward treatment guidelines for the 
use of Saccharomyces boulardii in the management of GE, but often in a mixed population of both pediatric and 
adult participants.   
 
Except for the non-specification that participants needed to be admitted to hospital for the duration of the 
intervention, the systematic review conducted by Szajewska et al (2007)33 is the only closest match to the 
inclusion criteria of the current systematic review.  These authors33 conducted a systematic review of only RCTs 
to test the effectiveness of Saccharomyces boulardii in treating AGE in children.  Five RCTs involving 619 
participants were included.  The combined data showed that Saccharomyces boulardii significantly reduced the 
duration of diarrhea when compared to the control arm.  Using a fixed model and random effec ts model, this 
yeast probiotic still produced a WMD of -1.1 days (95% CI: -1.2 to -0.8).  Although a smaller study sample 
(n=548) and a smaller WMD of -0.57 days (95% CI: -0.83 to -0.30), the current systematic review also produced 
results in favor of use of Saccharomyces boulardii to treat AGE, but specifically in the pediatric patient.  Again, 
like results from McFarland (2010)29 and the current systematic review, significant changes in GE experienced 
by the Saccharomyces boulardii versus the control group were noted on Day 3, in addition to Day 6 and Day 7.  
Furthermore, these authors33 reported than in one RCT study (n=88), the risk of diarrhea lasting in excess of 7 
days was significantly reduced in the Saccharomyces boulardii versus the control group (RR 0.25; 95% CI: 0.08 
to 0.83; number-needed-to-treat=5, 95% CI: 3 to 20).  As a result, these authors33 concluded that 
Saccharomyces boulardii displayed moderate clinical benefit in otherwise healthy infants and children with AGE.  
 
The systematic review conducted by McFarland (2010)29 used only RCTs and pre-clinical studies to assess the 
efficacy and safety of Saccharomyces boulardii on various forms of GE, one of which was AGE.  The number of 
studies reporting on the use of Saccharomyces boulardii to treat AGE was limited, with these authors only 
referring to two studies in which Saccharomyces boulardii or a placebo was offered to a small sample (n=92) of 
the adult population.  In the first study, participants receiving Saccharomyces boulardii at a dose of (8 x 109 /day) 
for eight consecutive days showed a significant improvement in GE severity score by Day 3 of treatment (5.5 ± 
6.8; P = 0.04) compared to the placebo group (6.7 ± 8.7).  The time point of Day 3 is significant as similar 
findings were found in the current systematic review.  During the treatment period for four of the included 
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studies41,45,47,53, Day 3 of treatment was a turning point where participants showed a significant reduction in stool 
frequency, some even with resolution of GE.   
 
The second study reported by McFarland (2010)29 involved fewer patients (n=57) whom were offered 
Saccharomyces boulardii as (1.5 x 1010 /day) and for a longer period of ten days.  It was noted that after four 
weeks of treatment, all participants receiving Saccharomyces boulardii were cured compared with only 19 
percent of those not given the yeast probiotic.  Overall, the results of the meta-analysis conducted by McFarland 
(2010)29 show that in 27 out of 31 studies (including 5029 study participants), Saccharomyces boulardii was 
found to be most efficacious and safe in 84 percent of the treatment arms.  This reporting on efficacy 
complements findings in the current systematic review, i.e. participants offered Saccharomyces boulardii were 
likely to experience duration of GE at least half a day less than participants not offered Saccharomyces boulardii.  
Although this figure might not seem high, it was found to be statically significant (P < 0.0001).   
 
However, it must be noted that the overall results from the meta-analysis conducted by McFarland (2010)29 
differed in many areas with the meta-analysis conducted in the present systematic review.  Aside from 
McFarland (2010)29 using a study population (i.e. adult) different from the current systematic review (i.e. 
pediatrics between 0 to 16 years), McFarland (2010)29 also included use of Saccharomyces boulardii in treating 
GE that resulted from a wide variety of causes.  By way of example, one of the studies mentioned above treated 
participants with acute Entamoeba histolytica dysentery.  The current systematic review was specific to only 
include studies addressing GE caused by Rotavirus.  Furthermore, in- and out-patient status, duration of 
treatment period and dosages offered differed drastically between the two systematic reviews.   
 
The Cochrane Review carried out by Allen et al (2010)15 was another systematic review aimed at assessing the 
effect and, like the current systematic review, safety of probiotics, including Saccharomyces boulardii, in treating 
GE.  This review was much larger than the systematic reviews mentioned earlier as it included 63 studies with a 
combined 8014 participants.  Within this large pool of s tudies, 56 included infants and young children.  The 
included studies took the form of either RCTs or quasi-RCTS that compared the effect of a specified probiotic 
with either a placebo/no probiotic in people with AGE.  The overall result was indicative of probiotics (including 
Saccharomyces boulardii), having the ability to reduce the duration of GE.  But like the assessment made by 
McFarland (2010)29, these authors15 also acknowledged challenges faced with conducting their systematic 
review.  Included studies in their systematic review varied in their definitions of both AGE and AGE-resolution, 
the studies were all undertaken in a wide range of different settings and there was variation in terms of the 
organism tested, dosage offered and participant characteristics.  The authors15 concluded that if used alongside 
ORS, probiotics (including Saccharomyces boulardii), appeared to be safe and has the potential to reduce AGE 
duration and reduce stool frequency.   
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The systematic review conducted by Pan et al (2012)40 was similar to the current systematic review in that three 
of the studies43,50,53 included in the current systematic review also featured in Pan et al’s (2012)40  list of included 
studies.  Similar to challenges experienced with the current systematic review, these authors also had difficulty 
retrieving suitable RCTs for inclusion, i.e. only eight included studies from a total pool of 678.  These eight 
studies included participants that ranged between the ages of 1 month up to 12 years, were all described as 
being randomized into either the Saccharomyces boulardii or the control (commercialized ORS) group, received 
about the same dosage of Saccharomyces boulardii (500mg/d) but with only 2 studies indicating smaller doses 
of Saccharomyces boulardii (250mg/d) for participants <12 months.  All participants received the intervention for 
a period of five to seven days, with only one study continuing to follow the participants up until Day 14.  Although 
only 25 percent of the included studies reported on the cause of the GE, and not all studies were carried out in a 
hospital setting, the authors reported that the results of their meta-analysis showed that the Saccharomyces 
boulardii group was more effective than the control group with decreasing the following: duration of diarrhea (MD 
-0.92, 95% CI: -1.32 to -0.52), stool frequency on Day 3 (MD -1.92, 95% CI: -1.63 to -0.95), Day 4 (MD -0.51, 
95% CI: -0.89 to -0.33), and Day 7 (MD -0.44, 95% CI: -0.72 to -0.16), respectively.  Despite only 25 percent of 
included studies indicating the cause of the diarrhea in each of their studies, the authors concluded that 
Saccharomyces boulardii displayed therapeutic effects in treating children with AGE.   
 
Based on the above few reviews, it would seem justified to conclude that Saccharomyces boulardii has 
displayed no harmful effects and has shown consistent potential to significantly decrease the duration of AGE in 
the (-adult and-) pediatric population.   
 
4.6  STRENGTHS AND LIMITATIONS OF THIS SYSTEMATIC REVIEW 
There have been multiple studies, including RCTs done on probiotics (including Saccharomyces boulardii) and 
its effects on human health.  It was challenging to access studies that met all the inclusion criteria stipulated in 
this systematic review, i.e. Saccharomyces boulardii + pediatric population + no active ingredients aside from 
Saccharomyces boulardii + diagnosed with Rotavirus-causing AGE + admitted to a hospital setting for the 
duration of the study.  From the initial search, only ten studies were able to successfully meet these inclusion 
requirements.  That being said, these specifications did lead to a more appropriate comparison, and therefore 
pooling of results between the intervention and control groups of each individual study.   
 
During the literature search phase and owing to the use of an all-inclusive search string, >2200 hits were 
obtained, some being clearly non-relevant.  A single reviewer (MP) conducted the initial screening phase so as 
to sharpen the research team’s focus on studies that appeared to be most relevant to the current systematic 
review.  This might be viewed as an area of bias in this systematic review.  However, based on the final ten 
studies included in this review, and the inclusion of the same/similar studies in other systematic reviews, it is 
more than likely that this screening process was not highly compromised. 
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The area that might be considered an absolute weakness in this systematic review is the use of English-
language studies only.  As mentioned earlier, an all-inclusive search string was used initially.  Once foreign 
language studies were identified, attempts were made to access English versions of these references, i.e. the 
primary authors were emailed directly, or the Medical Librarian tried sourcing the respective articles via the 
University’s library.  In both instances, the primary reviewer (MP) failed to access these foreign language 
studies, i.e. study authors either did not respond to the enquiry or replied in the negative, or the University library 
was not able to access the journal or study based on its publication date and access restrictions.  As a result, the 
research team was forced to collectively agree to remove these studies from the list of potential studies for 
inclusion, and acknowledge this to be a limitation in this systematic review. 
 
Another concern would be the various geographical settings in which the ten included studies were conducted.  
Five different countries were identified, namely Pakistan, Myanmar, Turkey, India and Brazil.  The nutritional 
status of the participants would vary drastically e.g. the study by Ozkan et al47 was conducted in Turkey where 
mild/moderate malnutrition was seen in only 12.5 percent of the Saccharomyces boulardii group and 9.1 percent 
in the control group, with mortality statistics considered low in this pediatric population.8-10  Myanmar, which is 
where one study53 was conducted, would vary drastically from the aforementioned study because it is a country 
considered as having a high childhood mortality risk.8-10  That being said, one of the criteria stipulated in this 
research review was to exclude studies including under-nourished participants, thereby removing any associated 
confounding effect. 
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CHAPTER 5 
CONCLUSION AND RECOMMENDATIONS 
 
5.1 CONCLUSIONS 
The purpose of this systematic review was to assess the efficacy and safety of the yeast probiotic 
Saccharomyces boulardii in the treatment of AGE in the pediatric hospitalized population.  The primary 
outcomes under investigation were to assess the overall efficacy of Saccharomyces boulardii on the duration of 
GE in the pediatric patient, and to establish the safety of this yeast probiotic for use in the pediatric hospitalized 
patient.  Additional secondary outcomes included the impact of this yeast probiotic on length of hospital stay and 
associated costs.   
 
Overall, the results indicate that Saccharomyces boulardii shortened the duration of AGE caused by Rotavirus 
(in days) when compared to the control/placebo group, with the included studies displaying little/no 
heterogeneity.  In addition, no adverse effects were associated with the use of this yeast probiotic in treating 
AGE in otherwise healthy children.  Therefore, the results of the current systematic review indicate that there is a 
potential benefit associated with the use of Saccharomyces boulardii to treat AGE in the pediatric 
patient.15,17,18,24-27,32,44-45,47-49,53   
 
Offering this unique yeast probiotic at a dose of 250mg once to twice per day for up to five to seven days has 
shown some statistically significant benefit with decreasing the duration of AGE.  Although no statistical 
difference was noted between the groups with the number of days in hospital, the days to appearance of the first 
semi-formed stool were found to be less in the Saccharomyces boulardii group as compared to the control 
group.15,17,18,24-27,32,44-45,47-49,53 
 
However, owing to factors such as small sample sizes, unclear and inconsistent quality of methodology, 
reporting bias owing to source of funding and support, a definitive conclusion and recommendation for the use of 
a specific probiotic like Saccharomyces boulardii to be used as treatment or treatment adjunct for AGE in the 
pediatric hospitalized patient cannot yet be made.   
 
5.2 RECOMMENDATIONS FOR FUTURE RESEARCH 
Future research initiatives investigating the subject of the benefits/harm associated with the use of 
Saccharomyces boulardii must therefore endeavor to consist of larger RCTs which: 
 Minimize heterogeneity associated with study participants enrolled, 
 Clearly pre-define aetiologies’ e.g. GE, AGE etcetera  
 Minimize methodological variability (e.g. blinding),  
 Standardize the presentation in which the intervention is offered, and 
 Single-strain probiotic investigations. 
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APPENDIX 6.1: Study Eligibility Form 
Eligibility Form: A systematic review of the efficacy and safety of Saccharomyces boulardii in the 
treatment of acute gastroenteritis in the pediatric population.  
 
Study Eligibility Form  
Saccharomyces boulardii  in the treatment of AGE in the pediatric population 
 
Review er ID          Review er ID 
Study ID        Study ID 
 
Type of study  Type of study 
Is the study a 
randomised 
controlled trial? 
YES 
   ↓ 
UNCLEAR 
       ↓ 
NO 
  ↓ 
 Is the study a 
randomised 
controlled trial? 
YES 
   ↓ 
UNCLEAR 
       ↓ 
NO 
  ↓ 
Go to next question Exclude: 
 
 Go to next question Exclude: 
 
Types of participants  Types of participants 
Are the 
participants 
betw een 0-16 
years? 
YES 
   ↓ 
UNCLEAR 
        ↓ 
NO 
  ↓ 
 Are the 
participants 
betw een 0-16 
years? 
YES 
   ↓ 
UNCLEAR 
       ↓ 
NO 
  ↓ 
Go to next question Exclude:   Go to next question Exclude:  
Trial Intervention  Trial Intervention 
Did the 
participants in the 
study have acute 
gastroenteritis as 
defined by WHO? 
YES 
   ↓ 
UNCLEAR 
       ↓ 
NO 
  ↓ 
 Did the 
participants in  
the study have 
acute 
gastroenteritis as 
defined by  
WHO? 
YES 
   ↓ 
UNCLEAR 
       ↓ 
NO 
  ↓ 
Go to next question Exclude: 
 
  Exclude: 
 
Was the 
intervention a 
Saccharomyces 
boulardii 
supplement? 
YES 
   ↓ 
UNCLEAR 
       ↓ 
NO 
  ↓ 
 Was the 
intervention a 
Saccharomyces 
boulardii 
supplement? 
YES 
   ↓ 
UNCLEAR 
       ↓ 
NO 
  ↓ 
Go to next question Exclude:    Exclude:  
 
Was the 
intervention 
administered in a 
hospital setting? 
YES 
   ↓ 
UNCLEAR 
       ↓ 
NO 
  ↓ 
 Was the 
intervention 
administered in a 
hospital setting? 
YES 
   ↓ 
UNCLEAR 
       ↓ 
NO 
  ↓ 
Go to next question Exclude: 
 
 Go to next question Exclude: 
 
Types of comparison  Types of comparisons 
Was a proper 
control used 
[placebo, no 
intervention, 
other 
supplement(s)]? 
YES 
   ↓ 
UNCLEAR 
      ↓ 
NO 
  ↓ 
 Was a proper 
control used 
[placebo, no 
intervention, 
other 
supplement(s)]? 
YES 
   ↓ 
UNCLEAR 
      ↓ 
NO 
  ↓ 
Go to next question Exclude:   Go to next question Exclude:   
Outcomes  Outcomes 
Was at least one 
of the pre-
specif ied 
outcomes in the 
protocol 
addressed? 
YES 
   ↓ 
UNCLEAR 
      ↓ 
NO 
  ↓ 
 Was at least one 
of the pre-
specif ied 
outcomes in the 
protocol 
addressed? 
YES 
   ↓ 
UNCLEAR 
      ↓ 
NO 
  ↓ 
Go to next question Exclude:   Go to next question Exclude:   
Other  Other 
Any other reasons 
for excluding 
study? 
Please specify. 
 
 
 
NO 
  ↓ 
YES 
   ↓ 
 Any other reasons 
for excluding 
study? 
Please specify. 
 
 
 
 
NO 
  ↓ 
YES 
   ↓ 
Include, subject to 
clarif ication of 
‘unclear’ points 
Exclude 
because 
of: 
 Include, subject to 
clarif ication of 
‘unclear’ points 
Exclude 
because 
of: 
 
 
 
 
 
Final Decision: Include  Exclude  Final Decision: Include Exclude 
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APPENDIX 6.2: Data Extraction Form 
General Information 
Review title / ID  
Study ID (surname of first author and year )  
Authors contact details &/or reference citation  
Publication type  
Name of review author completing this form   
Date form completed  
Notes 
 
Methods 
 Descriptions as stated in report/paper  Location in text or source 
Aim of study (e.g. efficacy)   
Design (e.g. parallel, RCT)  
Method of recruitment   
Inclusion criteria  
 
Exclusion criteria  
Informed consent Y N Unclear  
 Ethical approval needed / 
obtained 
Y N Unclear  
Funding (source/amount)   
Statistical methods used 
and their appropriateness 
  
Notes:  
 
Participants 
 Description  Location in text or source 
Population description   
Setting  
Total no. randomised   
Age  (range, mean, SD)   
Gender Male Female   
Ethnicity   
Baseline imbalances   
Withdrawals / exclusions   
Severity of illness   
Co-morbidities   
Other socio-
demographics 
 
Subgroups measured   
Subgroups reported  
Notes:  
 
Intervention groups 
 Description as stated in report/paper Location in text or source 
Group name   
No. randomised to group  
Description   
Duration of treatment 
period 
 
Timing (e.g. frequency, 
duration of each episode) 
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Delivery of intervention 
(e.g. in stages, timing, 
frequency, duration, how?) 
 
Providers (e.g. who delivers 
the intervention, the no. of 
providers; training of 
providers in delivery of 
intervention) 
  
Co-interventions   
Economic information   
Resource requirements   
Notes:    
 
Outcomes 
 Description as stated in report/paper Location in text or source 
Outcome type    
Outcome name   
Time points measured 
(specify whether from start or 
end of intervention) 
 
Time points reported  
Outcome definition (with 
diagnostic criteria if relevant) 
  
Person measuring/ 
reporting 
  
Unit of measurement    
Imputation of missing data 
(e.g. assumptions made for 
ITT analysis) 
  
Assumed risk estimate (e.g. 
baseline or population risk 
noted in Background) 
  
Power (e.g. power & sample 
size calculation, level of 
power achieved) 
  
Notes:    
 
Risk of bias assessment 
Domain 
Risk of bias rating Support for judgment Location in text 
Low  High Unclear   
Random sequence 
generation (selection bias) 
Low  High Unclear   
Allocation concealment 
(selection bias) Low  High Unclear 
  
Blinding of participants 
and personnel (performance 
bias) 
Low  High Unclear 
  
Blinding of outcome 
assessment (detection bias) 
Low  High Unclear  
Incomplete outcome data 
(attrition bias) Low  High Unclear 
 
Selective outcome 
reporting? (reporting bias) 
Low  High Unclear  
Other bias Low  High Unclear   
Notes:    
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Data and analysis 
Continuous outcome Description as stated in report/paper Location in text or source 
Comparison   
Outcome  
Subgroup  
Time point  
Post-intervention or 
change from baseline? 
 
 
Outcome Timing of 
outcome 
(days/months) 
Intervention 
S boulardii & ORS 
Control 
ORS 
alone 
Notes 
Mean 
duration 
of 
diarrhea 
    
Any other results reported   
No. missing participants    
Reasons missing    
No. participants moved 
from other group 
   
Reasons moved    
Unit of analysis   
Notes:    
 
Other information / miscellaneous 
 Description as stated in report/paper Location in text or source  
Key conclusions of study 
authors 
  
References to other 
relevant studies 
  
Correspondence required 
for further study 
information (from whom, 
what and when) 
 
Notes:    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from http://cccrg.cochrane.org/author-resources 
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APPENDIX 6.3: Risk-of-bias tool  
Sequence generation 
 
Was the allocation sequence adequately generated? (Adequate sequence generation?) 
Criteria for a judgment of “YES” 
(i.e. low risk of bias)  
The investigation describes a random component in the sequence generation process such as: 
 Referring to a random number table; 
 Using a computer random number generator; 
 Coin tossing; 
 Shuff ling cards or envelopes; 
 Throw ing dice; 
 Draw ing of lots; 
 Minimization 
Criteria for the judgment of “NO” 
(i.e. high risk of bias) 
The investigators describe a non-random component in the sequence generation process.   
 
Usually, the description w ould involve some systematic, non-random approach, for example: 
 Sequence generated by odd or even date of birth; 
 Sequence generated by some rule based on date (or day) of admission; 
 Sequence generated by some rule based on hospital or clinic record number; 
 
Other non-random approaches happen much less frequently than the systematic approaches 
mentioned above and tend to be obvious.  They usually involve judgment or some method of 
non-random categorization of participants, for example: 
 Allocation by judgment of the clinician; 
 Allocation by preference of the participant; 
 Allocation based on the results of a laboratory test or a series of tests. 
Criteria for the judgment of 
“UNCLEAR” (uncertain risk of bias) 
Insuff icient information about the sequence generation process to permit judgment of “Yes” or 
“No”. 
Allocation generation 
 
Was allocation adequately concealed? (Adequate allocation concealment?) 
Criteria for the judgment of “Yes”  
(i.e. loss risk of bias) 
Participants and investigators enrolling participants could not foresee assignment because of 
one of the follow ing, or an equivalent method, w as used to conceal allocation: 
 Central allocation (including telephone, w eb-based and pharmacy-controlled 
randomization); 
 Sequentially numbered drug containers of identical appearance. 
Criteria for the judgment of “NO” 
(i.e. high risk of bias) 
Participants or investigators enrolling participants could possibly foresee assignments and thus 
introduce selection bias, such as allocation based on: 
 Using an open random allocation schedule (e.g. a list of random numbers); 
 Assignment envelopes w ere used without appropriate safeguards (e.g. if  envelopes were 
unsealed or non-opaque or not sequentially numbered); 
 Alternation or rotation; 
 Date of birth; 
 Case record number 
Criteria for the judgment of 
“UNCLEAR” (uncertain risk of bias) 
Insuff icient information to permit judgment of “Yes” or “No”.   
 
This is usually the case if the method of concealment is not described or not described in 
suff icient detail to allow  a definite judgment – for example, if  the use of assignment envelopes is 
described, but it remains unclear w hether envelopes were sequentially numbered, opaque and 
sealed. 
 
Blinding of participants, personnel and outcome assessors 
 
Was knowledge of the allocated interventions adequately prevented during the study? (Blinding?) 
Criteria for the judgment of “Yes”  
(i.e. loss risk of bias) 
Any one of the follow ing: 
 No blinding, but the review  authors judge that the outcome/outcome measurement are not 
likely to be influenced by lack of blinding; 
 Blinding of participants and key study personnel ensured; blinding unlikely to have been 
broken. 
Criteria for the judgment of “NO” 
(i.e. high risk of bias) 
Any one of the follow ing: 
 No blinding or incomplete blinding, and the outcome or outcome measurement is likely to 
be influenced by lack of blinding; 
 Blinding of key study participants and personnel attempted, but likely that the blinding 
could have been broken. 
Criteria for the judgment of 
“UNCLEAR” (uncertain risk of bias) 
Any one of the follow ing: 
 Insuff icient information to permit judgment of “Yes” or “No”; 
 The study did not address this outcome. 
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Incomplete outcome data 
 
Were incomplete outcome data adequately addressed? 
Criteria for the judgment of “Yes” 
(i.e. loss risk of bias) 
Any one of the follow ing: 
 No missing outcome data; 
 Reasons for missing outcome data unlikely to be related to true outcome (for survival data, 
censoring unlikely to be introducing bias); 
 Missing outcome data balanced in numbers across intervention groups, with similar 
reasons for missing data across groups; 
 For dichotomous outcome data, the proportion of missing outcomes compared w ith 
observed event risk not enough to have a clinically relevant impact on the intervention 
effect estimate; 
 For continuous outcome data, plausible effect size (difference in means or standardized 
difference in means) among missing outcomes not enough to have a clinically relevant 
impact on observed effect size. 
Criteria for the judgment of “NO” 
(i.e. high risk of bias) 
Any one of the follow ing: 
 Reason for missing outcome data likely  to be related to true outcome, w ith either 
imbalance in numbers or reasons for missing data across intervention groups; 
 For dichotomous outcome data, the proportion of missing outcomes compared w ith 
observed event risk enough to induce clinically relevant bias in intervention effect estimate; 
 For continuous outcome data, plausible effect size (difference in means or standardized 
difference in means) among missing outcomes enough to induce clinically relevant bias in 
observed effect size; 
 “As-treated” analysis done with substantial departure of the intervention received from that 
assigned at randomization.  
Criteria for the judgment of 
“UNCLEAR” (uncertain risk of bias) 
Any one of the follow ing: 
 Insuff icient reporting of attrition/exclusions to permit judgment of “Yes” or “No” (e.g. 
number randomized not stated, no reasons for missing data provided); 
 The study did not address this outcome. 
Selective outcome reporting 
 
Are reports of the study free of suggestion of selective outcome reporting? (Free of selective reporting?) 
Criteria for the judgment of “Yes”  
(i.e. loss risk of bias) 
The study protocol is available and all of the study’s pre-specif ied (primary and secondary) 
outcomes that are of interest in the review  have been reported in the pre-specif ied way.  
Criteria for the judgment of “NO” 
(i.e. high risk of bias) 
Any of the follow ing: 
 Not all of the study’s pre-specified primary outcomes have been reported; 
 One or more primary outcomes is reported using measurements, analysis methods or 
subsets of the data (e.g. subscales) that w ere not pre-specified; 
 One or more reported primary outcomes w ere not pre-specified (unless clear justif ication 
for their reporting is provided, such as an unexpected adverse effect); 
 One or more outcomes of interest in the review  are reported incompletely so that they 
cannot be entered in a meta-analysis. 
Criteria for the judgment of 
“UNCLEAR” (uncertain risk of bias) 
Insuff icient information to permit judgment of “Yes” or “No”.  It is likely that the majority of 
studies w ill fall into this category. 
 
Other potential threats to validity 
 
Was the study apparently free of other problems that could put it at a risk of bias? (Free of other bias?) 
Criteria for the judgment of “Yes”  
(i.e. loss risk of bias) 
The study appears to be free of other potential sources of bias. 
Criteria for the judgment of “NO” 
(i.e. high risk of bias) 
There is at least one important risk of bias.  For example, the study: 
 Had a potential source of bias related to the specif ic study design used; or 
 Stopped early due to some data-dependent process (including a formal-stopping rule); or 
 Had extreme baseline imbalance; or 
 Has been claimed to have been fraudulent. 
Criteria for the judgment of 
“UNCLEAR” (uncertain risk of bias) 
There may be risk of bias, nut there is either: 
 Insuff icient information to assess whether an important risk of bias exists; or 
 Insuff icient rationale or evidence that an identif ied problem w ill introduce bias. 
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APPENDIX 6.8: Characteristics of included studies 
Billoo AG, Memon MA, Khaskheli SA, Murtaza G, Iqbal K, Shekhani MS, Siddiqi AQ. Role of a probiotic 
(Saccharomyces boulardii) in management and prevention of diarrhea. World Journal of 
Gastroenterology 2006 July 28;12(28):4557-4560. 
Methods Study design: RCT 
Study duration: 5 day active treatment phase, followed for 2 months afterwards. 
Study location: Low income community, Kharadar General Hospital, Karachi 
Participants Number of participants: 100 children ranging 2months to 12 years 
Intervention group: 50; Control group: 50 
Interventions Intervention: Sb, 250mg twice per day x 5 days, WHO-CDD protocol. 
Control: WHO-CDD protocol only. 
Outcomes Primary outcomes: Duration of diarrhea, mean number of stools per day, number of 
episodes of diarrhea, percentage weight gain. 
Notes No placebo mentioned/described. 
Funding: Acknowledged support of Laboratoires Biocodex and Hilton Pharma for this 
study. Hilton Pharma supplied Sb (Enflor) and logistic support for the follow up of 
patients during the course of the study 
Bias Authors 
judgment 
Support for judgment 
Random sequence 
generation 
Unclear risk Quote “100 children were randomized into two groups”.  
Allocation 
concealment 
High risk No description/mention of any placebo used in the control group. 
Blinding of 
participants/personnel 
Unclear risk All personnel and participants were blinded during the 5-day 
treatment period. 
Blinding of outcome 
assessment 
Unclear risk There is the possibility that follow up could have been blinded, 
but parents knew if their child received the dissolved treatment or 
not. 
Incomplete outcome 
data 
Low risk  
Selective reporting Low risk  
Other bias 
 
 
 
Low risk 
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Burande MA. Comparison of efficacy of Saccharomyces boulardii strain in the treatment of acute 
diarrhea in children: A prospective, single-blind, randomized controlled clinical trial. Journal of 
Pharmacology and Pharmacotherapeutics July-September 2013;4(3):205-208. 
Methods Study design: Prospective, parallel, single-blinded RCT 
Study duration: July 2009 to July 2011 
Study location: tertiary care hospital attached with Medical College, India 
Participants Number of participants: 72 
Intervention group: 35; Control group: 35 
Interventions Intervention: Sb, 250mg x 2 daily for 5 days, ORS and zinc 
Control: ORS and zinc supplement only 
Outcomes 1. Days to recovery from loose motions 
2. Days to recovery from vomiting 
Notes  
Bias Authors 
judgment 
Support for judgment 
Random sequence 
generation 
Low risk Patients were assigned a study number corresponding to their 
entry in the trial.  They were randomized by simple randomization 
with the help of computer-generated random numbers. 
Allocation 
concealment 
Unclear risk Quote: “As per the allocation, drugs were prescribed to the 
patients by the pediatrician”.   
Comment: It is not clear if the parents knew of the different 
treatment groups. 
Blinding of 
participants/personnel 
Unclear risk Single blind study with parents being blind to allocation used.  
However, no placebo was given, so parents could compare 
treatments and differences. 
Blinding of outcome 
assessment 
Low risk The passage of two consecutive formed stools as per the Kings 
scoring system or having no stool till the 12 hour mark. 
Incomplete outcome 
data 
Low risk No obvious missing data or missing outcomes. 
Selective reporting Low risk No obvious missing data or missing outcomes. 
Other bias Unclear risk Quotes: “After approval from institutional ethical committee … 
attached to a Medical College.” 
Comment: No details about funding etc. 
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Corrêa NBO, Penna FJ, Lima FLMS, Nicoli JR, Filho LAP. Treatment of Acute Diarrhea with 
Saccharomyces boulardii in Infants. Journal of Pediatric Gastroenterology and Nutrition. June 20 
2011;53:497-501. 
Methods Study design: Double blinded, randomized, placebo-controlled, parallel-group study 
Study duration: 5 days 
Study location: Two hospitals in Goiaˆnia, Goia´s, Brazil. 
Participants Number of participants: 186 mixed gender children, 6-48 months with no other 
diarrhea episode or antibiotic use 2 weeks before trial, and AGE within 72 hrs before 
hospitalization. 
Intervention: 90; Control: 86 
Interventions Intervention: Sb, 200mg capsules, offered every 12 hours for 5 days.  
Control: Placebo offered every 12 hours for 5 days. 
Outcomes 1. Clinical cure of diarrhoea. 
2. Frequency of diarrhoea during the first 3 days after start of intervention. 
3. Frequency of diarrhoea 3 days after start of intervention for patients presenting or 
not presenting with rotavirus. 
Notes Funding not clear: “The study was supported by Conselho Nacional de 
Desenvolvimento Cientı´ ﬁco e Tecnolo´gico (CNPq) and Coordenac¸a˜o de 
Aperfeic¸oamentodo Pessoal de Ensino Superior (CAPES).” 
Bias Authors 
judgment 
Support for judgment 
Random sequence 
generation 
Low risk Patients assigned a study no corresponding to their entry into 
trial; randomized by simple randomization with computer-
generated random nos. 
Allocation 
concealment 
Low risk Capsules were randomly coded by computer-generated numbers 
and distributed to the attending staff, which was composed of 2 
physicians, 2 nurses and 2 nutritionists. 
Blinding of 
participants/personnel 
Low risk Both placebo and lyophilized Sb were packaged in identical 
capsules.  Powders on both types of capsules were similar in 
texture and color, and the attending staff was unaware which 
product was being administered.  
Blinding of outcome 
assessment 
Low risk Clearly defined as – when evacuation frequency was <3 times 
per day or the stool consistency improved for at least 24hrs.  If no 
improvement was noted in 4 days, therapy was stopped and child 
was remanded for further treatment of diarrhea.  
Incomplete outcome 
data 
Low risk ITT and PP analyses performed. 
Selective reporting Low risk Clearly stated outcomes were used. 
Other bias Unclear risk None. 
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Dalgic N, Sancar M, Bayraktar B, Pullu M, Hasim O. Probiotic, zinc and lactose -free formula in children 
with rotavirus diarrhea: Are they effective? Pediatrics International January 11 2011;53:677-682. 
Methods Study design: Prospective, randomized, single-blind, controlled trial. 
Study duration: September 2008 and June 2010 
Study location: Sisli Etfal Training and Research Hospital, Turkey 
Participants Number of participants: 480 children, ages 1 to 28 months 
Participants: 60 in each of the 8 groups. 
Interventions Group 1 (Sb, 250mg/d x 5 days) 
Group 2 (Zinc acetate x 20mg/d x 5 days) 
Group 3 (Lactose-free formula offered as required) 
Group 4 (Sb, 250mg/d + Zinc acetate x 20mg/d) x 5 days 
Group 5 (Sb, 250mg/d + Lactose-free formula as required) x 5 days 
Group 6 (Zinc acetate 20mg/d + Lactose-free formula) x 5 days 
Group 7 (Sbx250mg/d+Lact-free form+Zinc acetate x20mg/d) x 5 days 
Group 8 (only oral and/or parenteral rehydration solutions) 
Outcomes 1. Duration of diarrhoea. 
2. Duration of hospitalization. 
3. Time to resolution of vomiting. 
4. Time to resolution of fever. 
Notes For rehydration, patients were offered ORS with a composition as recommended by 
the ESPGHAN.  If necessary, because of excessive vomiting and clinical signs of 
dehydration, parenteral rehydration was established.  The study preparation was 
given right after randomization, rehydration was not awaited. 
Bias Authors 
judgment 
Support for judgment 
Random sequence 
generation 
Low risk The patients were randomly assigned from a computerized 
admissions list to 1 of 8 different treatment groups described. 
Allocation 
concealment 
Unclear risk How participants/caregivers and researchers were kept in the 
dark is not clearly stated. 
Blinding of 
participants/personnel 
Unclear risk This is a single blind study.  However, it is not clear how the 
different treatments were made to look alike to the patients. 
Blinding of outcome 
assessment 
Unclear risk The authors do not provide definitions for all outcomes; who 
conducted these assessments is not clear. 
Incomplete outcome 
data 
Low risk Reported that all 480 participants completed the study. 
Selective reporting Low risk All stated outcomes were reported clearly. 
Other bias Unclear risk Comments: Question the likelihood that all 480 participants 
completed the study.  Intervention “lactose-free formula” not well 
described in terms of amounts and duration of use. 
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Erdoğan Ö, Tanyeri B, Torun E, Gönüllü E, Arslan, Erenberk U, Öktem F. The Comparition of the 
Efficacy of Two Different Probiotics in Rotavirus Gastroenteritis in Children. Journal of Tropical 
Medicine 2012;Article ID 787240:1-5. 
Methods Study design: Prospective, randomized trial 
Study duration: October 2009 and May 2010 
Study location: Bezmialem Hospital, Turkey 
Participants Number of participants: 75 children aged 5 months and 5 years. 
Intervention 1= 25; Intervention 2 = 25; Control = 25 
Interventions Group 1 (ORS, rapid refeeding with a normal diet, 282.5mg/d Saccharomyces 
boulardii) 
Group 2 (ORS, rapid refeeding with a normal diet, 30mg/d Bifidionbacterium lactis) 
Group 3 (ORS, rapid refeeding with a normal diet) 
Outcomes 1. Duration time of diarrhoea; 2. Vomiting episodes at follow up. 
Notes  
Bias Authors 
judgment 
Support for judgment 
Random sequence 
generation 
Unclear risk Simple comment that patients were divided into 3 groups of 25; 
no detail on how this was done randomly. 
Allocation 
concealment 
Unclear risk No details given on attempts to conceal allocation 
Blinding of 
participants/personnel 
High risk Control groups no placebo, not blinded. 
Blinding of outcome 
assessment 
Unclear risk Quote: “post discharged follow up were done by telephone to 
elicit … stool characteristics and consistency, and episodes of 
vomiting per day”. 
Comment: No training was provided to parents regarding 
reporting of these outcomes.  No details regarding who 
conducted the telephonic interviews.  
Incomplete outcome 
data 
Unclear risk No value vomiting episodes/d for group 3 on day 5. 
Selective reporting High risk Regarding diarrhea: subjects and methods (page 2) states they 
wanted to measure the frequency of diarrhea, plus the stool 
consistency.  But they only reported the duration time of the 
diarrhea. 
Other bias Low risk  
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Eren M, Dinleyici EC, Vandenplas Y. Clinical Efficacy Comparison of Saccharomyces boulardii and 
Yogurt Fluid in Acute Non-Bloody Diarrhea in Children: A Randomized Controlled, Open Label Study. 
American Journal of Tropical Medicine and Hygiene 2010;82(3):488–491. 
Methods Study design: randomized, prospective open-label study 
Study duration: April 2007 to January 2009 
Study location: Eskisehir Osmangazi University Hospital, Turkey 
Participants Number of participants: 55 children aged 5 months to 16 years. 
Group 1 = 28; Group 2 = 27 
Interventions Group 1 (Saccharomyces boulardii 250mg x 2 daily if >/= 2 years or 125mg x 2 daily 
if <2 years) 
Group 2 (Yoghurt fluid containing Lactobacillus bulgaricus and S. thermophiles, 107 
microorganisms/100ml; 30ml x 2 daily if >/= 2 years or 15ml x 2 daily if <2 years) 
Outcomes 1. Duration of diarrhoea. 
2. Resolution of diarrhoea at days 3 and 5. 
3. Days of hospitalization. 
4. Duration of vomiting. 
5. Cost-effectiveness of both interventions. 
Notes All patients that were mild or moderately dehydrated were treated according to WHO 
recommendations with ORS and zinc supplements (10mg/d in infants ≤ 6 months 
and 20mg/d in patients ≥ 6 months). 
Bias Authors 
judgment 
Support for judgment 
Random sequence 
generation 
Low risk Patients were randomized according to their patient ID number 
and enrolled in 2 groups.  Patients with odd ID numbers made up 
group A and patients with even ID numbers made up group B. 
Allocation 
concealment 
High risk Randomized, prospective but OPEN clinical trial – the two 
interventions differed visibly. 
Blinding of 
participants/personnel 
High risk Randomized, prospective but OPEN clinical trial – the two 
interventions differed visibly. 
Blinding of outcome 
assessment 
Low risk All patients were examined by 1 pediatric gastroenterologist on 
admission and re-evaluated every morning by the same doctor 
until resolution of diarrhea and discharged. 
Incomplete outcome 
data 
Low risk ITT & PP analyses were completed for two of the outcomes. 
Selective reporting Low risk Reported on all 5 outcomes initially mentioned. 
Other bias Low risk  
 
 
Stellenbosch University  https://scholar.sun.ac.za
 88 
 
Htwe K, Yee KS, Tin M, Vandenplas Y. Effect of Saccharomyces boulardii in the Treatment of Acute 
Watery Diarrhea in Myanmar Children: A Randomized Controlled Study. American Journal of Tropical 
Medicine and Hygiene 2008;78(2):214–216. 
Methods Study design: prospective, randomized controlled trial 
Study duration: not mentioned 
Study location: North Okkalapa General Hospital, Myanmar 
Participants Number of participants: 100 children aged 3 months to 10 years. 
Intervention group = 50; Control group = 50.  
Interventions Group 1 (Standard ORS to manage watery AGE, as per WHO guidelines x 5 days) 
Group 2 (Saccharomyces boulardii 250mg x 2 daily, standard ORS to manage 
watery AGE, as per WHO guidelines x 5 days) 
Outcomes 1. Duration of diarrhea. 
2. Stool frequency per day. 
Notes  
Bias   
Random sequence 
generation 
Low risk Patients were alternately assigned to receive the active product 
(Saccharomyces boulardii) in addition to ORS or ORS alone. 
Allocation 
concealment 
Unclear risk No details given regarding allocation concealment. 
Blinding of 
participants/personnel 
High risk Treatment group received ORS plus treatment and control group 
received only ORS; no placebo for blinding effect of participants.  
Blinding of outcome 
assessment 
Unclear risk Outcomes were recorded according to the information provided 
by the mother or attendant.  Specific definitions provided for each 
outcome, but not clear if mother and attendants were trained on 
this. 
Incomplete outcome 
data 
Unclear risk Table information indicates all subjects completed the study, but 
authors don’t discuss this in detail. 
Selective reporting Low risk All outcomes reported on. 
Other bias 
 
 
 
 
Low risk  
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Kurugöl Z, Koturoğlu G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta 
Pædiatrica 2005;94:44–47. 
Methods Study design: Randomized placebo controlled study 
Study duration: not mentioned 
Study location: Pediatric Department, Ege University in Izmir, Turkey  
Participants Number of participants: 200 children aged 3 months to 7 years. 
Intervention group = 100; Control group = 100. 
Interventions Group 1 (Saccharomyces boulardii, 250mg per day x 5 days) 
Group 2 (identical looking placebo diluted in water or juice x 5 days) 
Outcomes 1. Duration of diarrhea. 
2. Duration of watery diarrhea. 
3. Duration of fever. 
4. Duration of vomiting. 
5. Length of hospital stay. 
Notes ORT and normal food for their ages; parenteral rehydration if needed.  No serious 
adverse reactions in the Saccharomyces boulardii group were registered during the 
clinical study.  One child had a complaint of meteorism. 
Bias   
Random sequence 
generation 
Unclear risk Quote: “The patients were randomly allocated” 
Comment: No further info given about how randomization was 
achieved. 
Allocation 
concealment 
Unclear risk No information given about allocation concealment. 
Blinding of 
participants/personnel 
Low risk Group 1 (Saccharomyces boulardii) received 250mg/d; Group 2 
received an identical placebo. 
Blinding of outcome 
assessment 
High risk Parents were contacted telephonically to obtain data regarding 
stools and temperature.  Many flaws with this method as there is 
no mention of training being given to parents and there are no 
definitions for “watery diarrhea” versus “diarrhea”. 
Incomplete outcome 
data 
Unclear risk Data of 32 children who were excluded does not appear in any 
analyses (ITT); no reasons given. 
Selective reporting Low risk Stated to have observed adverse effects but very little info is 
given on this in the results section.  Not clearly stating to have 
observed duration of watery diarrhea, vomiting and fever, length 
of hospital stay, but this is very well reported in Table II.  
Other bias Unclear risk 
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Ozkan TB, Sahin E, Erdemir G, Budak F. Effect of Saccharomyces boulardii in Children with Acute 
Gastroenteritis and Its Relationship to the Immune Response. The Journal of International Medical 
Research 2007;35:201–212. 
Methods Study design: Randomized, double-blinded, placebo-controlled trial 
Study duration: October 2004 to March 2005 
Study location: Uludag University, Bursa, Turkey 
Participants Number of participants: 27 children aged 6 months and 10 years. 
Intervention group = 16; Control group = 11. 
Interventions Group 1 ((Saccharomyces boulardii 250mg x 2 daily x 7 days) 
Group 2 (Identical placebo x 2 daily x 7 days) 
Outcomes Daily stool frequency 
Notes All patients were given ORS and a lactose-free diet. 
Bias   
Random sequence 
generation 
Unclear risk Quote: “Patients were randomly allocated to one of two 
treatment groups”. 
Comment: A general statement was made that patients were 
randomly allocated to one of two treatment groups, but no further 
details on how this was done is described. 
Allocation 
concealment 
Unclear risk No details on how allocation concealment was achieved are 
provided. 
Blinding of 
participants/personnel 
Low risk Quote: “Control group (group 2) was given a placebo treatment 
that had identical characteristics and appearance”.  
Blinding of outcome 
assessment 
Unclear risk No details on the outcome assessment technique used have 
been reported. 
Incomplete outcome 
data 
Unclear risk No information on missing data. 
Selective reporting Low risk All outcomes were reported on. 
Other bias 
 
 
 
 
 
 
 
Low risk 
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Riaz M, Alam S, Malik A, Ali SM. Efficacy and Safety of Saccharomyces boulardii in Acute Childhood 
Diarrhea: A Double Blind Randomised Controlled Trial. Indian Journal of Pediatrics April 
2012;79(4):478–482. 
Methods Study design: double blind RCT. 
Study duration: May 2008 to September 2009 
Study location: Diarrhea Training and Treatment Unit, India 
Participants Number of participants: 108 children aged 3 months and 59 months. 
Group 1: 54; Group 2 = 54 
Interventions Group 1 ((Saccharomyces boulardii mixed with puffed rice powder, 250mg x 2 daily 
x 5 days) 
Group 2 (Placebo mixed with puffed rice powder, 2 daily x 5 days) 
Outcomes 1. Duration of post intervention diarrhea (time form enrolment to recovery).  
2. Frequency of stools. 
3. Time of first semi-formed stool. 
Notes  
Bias   
Random sequence 
generation 
Unclear risk Quote: “After informed consent the children were randomly given 
either a placebo …”. 
Allocation 
concealment 
Low risk Quote: “A non-departmental colleague not involved in study 
randomized (block randomization) these identical packets of 
placebo or Sb”. 
Blinding of 
participants/personnel 
Low risk Quote: “… placebo or Saccharomyces boulardii (SB) in identical 
packets mixed with puffed rice powder”. 
Blinding of outcome 
assessment 
Low risk Used clear discharge and recovery criteria, observed by the 
mother (who was blinded) and then personnel. 
Incomplete outcome 
data 
Low risk ITT and PP analysis were done. 
Selective reporting Low risk All stated outcomes were reported on. 
Other bias 
 
 
 
 
 
Low risk 
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APPENDIX 6.9: Risk-of-bias judgments for included studies  
BILLOO 2006 
ITEM Authors 
judgments 
Description 
Adequate 
sequence 
generation? 
Unclear Only a comment made that “100 children w ere randomized into tw o groups”. 
Adequate 
allocation 
concealment? 
No Saccharomyces boulardii was dissolved in w ater or semi-solid food, but the control group 
received nothing; but should have ideally received a placebo pow der. 
Adequate blinding 
of participants and 
personnel? 
Unclear All personnel and participants w ere unblended during the 5-day treatment period.   
Adequate blinding 
of outcome 
assessment?  
Unclear There is the possibility that follow -up personnel could have been blinded, but parents knew  if their 
child received the dissolved treatment or not. 
Incomplete 
outcome data 
addressed? 
Yes  
Free of selective 
reporting? 
Yes  
Free of other bias? Yes  
 
BURANDE 2013 
ITEM Authors 
judgments 
Description 
Adequate 
sequence 
generation? 
Yes Patients w ere assigned a study number corresponding to their entry in the trial.  They w ere 
randomized by simple randomization w ith the help of computer-generated random nos. 
Adequate 
allocation 
concealment? 
Unclear As per the allocation, drugs w ere prescribed to the patients by the pediatrician.  It is not clear if  
parents w ere aware of the different treatment groups. 
Adequate blinding 
of participants and 
personnel? 
Unclear Single blind study w ith parents being blind to allocation used.  How ever, no placebo w as given, 
so parents could compare treatments and differences.  
Adequate blinding 
of outcome 
assessment?  
Yes The passage of tw o consecutive formed stools as per the Kings scoring system or having no 
stool till the 12 hour mark. 
Incomplete 
outcome data 
addressed? 
Yes No obvious missing data or missing outcomes. 
Free of selective 
reporting? 
Yes No obvious missing data or missing outcomes. 
Free of other bias? No The study w as funded by DY Patil University and Management.  Dr Pravin Chavan helped w ith 
data collection.  No specif ic details provided regarding how  much funding and w here it w as used. 
 
CORRÊA 2011 
ITEM Authors 
judgments 
Description 
Adequate 
sequence 
generation? 
Unclear No information on the randomization of participants into 2 groups. 
Adequate 
allocation 
concealment? 
Yes The capsules w ere randomly coded by computer-generated numbers and distributed to the 
attending staff, 
Adequate blinding 
of participants and 
personnel? 
Yes Both the placebo and lyophilized Saccharomyces boulardii were packaged in identical capsules.  
Pow ders in both types of capsules w ere similar in texture and color; attending staff  were 
unaw are which product was being administered. 
Adequate blinding 
of outcome 
assessment?  
Yes Clearly defined as w hen evacuation frequency was <3 times per day or the stool consistency 
improved for at least 24 ours.  During the trial period, if  no improvement w as observed in 4 days 
of intervention, then the therapy w as stopped and the child w as sent for further treatment of 
diarrhea. 
Incomplete outcome 
data addressed? 
Yes PP and ITT w ere completed. 
Free of selective 
reporting? 
Yes Clearly stated outcomes w ere used. 
Free of other bias? Yes  None 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 93 
 
DALGIC 2011 
ITEM Authors 
judgments 
Description 
Adequate 
sequence 
generation? 
Yes The patients w ere randomly assigned from a computerized admissions list to one of the eight 
different treatment groups described. 
Adequate 
allocation 
concealment? 
Unclear No information about allocation concealment from participants, caregivers and researchers was 
achieved. 
Adequate blinding 
of participants and 
personnel? 
Unclear This is a single blind study but its not clear how  the different treatments were made to “look alike” 
to the participants. 
Adequate blinding 
of outcome 
assessment?  
Unclear It is not clear w ho performed the outcome assessments, but clear definitions are given. 
Incomplete 
outcome data 
addressed? 
Yes Authors report that all 480 participants completed the study. 
Free of selective 
reporting? 
Yes All outcomes mentioned in methods section are reported on in the results section. 
Free of other bias? Unclear The authors reported that among the 480 participants, no-one w as lost to w ithdrawal or exclusion 
or loss to follow -up.  Not enough information is given regarding the intervention “lactose-free 
formula” is given (e.g. amount offered and duration of use). 
 
ERDOGAN 2012 
ITEM Authors 
judgments 
Description 
Adequate 
sequence 
generation? 
Unclear A comment w ith no supporting details w as made that participants w ere divided into 3 groups of 
25. 
Adequate 
allocation 
concealment? 
Unclear No details given on attempts made to conceal allocation.  Control group w as not offered a 
placebo and therefore no blinding. 
Adequate blinding 
of participants and 
personnel? 
No Control group received no placebo (only the ORT and diet, like the other tw o groups) and w ere 
therefore not blinded. 
Adequate blinding 
of outcome 
assessment?  
Unclear No training w as provided to parents regarding reporting of these outcomes.  No details regarding 
w ho conducted the telephonic interviews. 
Incomplete 
outcome data 
addressed? 
Unclear No value supplied for the rate of vomiting episodes per day for group 3 on day 5.  
Free of selective 
reporting? 
No Stool characteristics and consistency were not reported on in the results section. 
Free of other bias? Yes  
 
EREN 2010 
ITEM Authors 
judgments 
Description 
Adequate 
sequence 
generation? 
Yes Patients w ere randomized according to their patient ID number and enrolled in 2 groups.  
Patients w ith an odd ID number composed group A and those w ith an even ID number composed 
group B. 
Adequate 
allocation 
concealment? 
No The tw o interventions differed visibly. 
Adequate blinding 
of participants and 
personnel? 
No This study design w as described as a randomized prospective but open clinical trial. 
Adequate blinding 
of outcome 
assessment?  
Yes All patients w ere examined by 1 pediatric gastroenterologist on admission and re-evaluated by 
the same doctor until resolution of diarrhea and discharge.  A standard evaluation tool (Bristol 
criteria) w as used to evaluate participants at each visit. 
Incomplete outcome 
data addressed? 
Yes ITT and PP analyses w ere completed for two of the outcomes. 
Free of selective 
reporting? 
Yes Authors reported on all 5 outcomes initially mentioned. 
Free of other bias? Yes  
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HTWE 2008 
ITEM Authors 
judgments 
Description 
Adequate 
sequence 
generation? 
Yes Patients w ere alternately assigned to treatment groups.  
Adequate 
allocation 
concealment? 
Unclear No details given regarding allocation concealment. 
Adequate blinding 
of participants and 
personnel? 
No The treatment group received ORS plus treatment and the control group received only ORS – no 
placebo w as mentioned. 
Adequate blinding 
of outcome 
assessment?  
Unclear Outcomes w ere recorded according to the information provided by the mother or attendant.  
Specif ic definitions provided for outcomes, but it w as not made clear if  mothers or attendants 
w ere trained for this.  
Incomplete 
outcome data 
addressed? 
Unclear Table information indicates all subjects completed the study, but authors don’t discuss this in any 
detail. 
Free of selective 
reporting? 
Yes All outcomes w ere reported on. 
Free of other bias? Yes  
 
KURUGOL 2005 
ITEM Authors 
judgments 
Description 
Adequate 
sequence 
generation? 
Unclear A general statement that patients w ere randomly allocated to treatment groups w as made but no 
further information on how  this w as done is provided. 
Adequate 
allocation 
concealment? 
Unclear No information given about allocation concealment. 
Adequate blinding 
of participants and 
personnel? 
Yes The patients in group 1 (Saccharomyces boulardii) received 250gm/d diluted w ith water or juice 
in accordance with the manufacturer’s instructions, whilst those in group 2 (placebo) received an 
identical placebo.   
Adequate blinding 
of outcome 
assessment?  
No Parents w ere contacted telephonically to obtain data reading stools and temperature.  This 
practice w ould present multiple opportunities for subjective reporting.  No mention of training 
being done for parents regarding how to assess changes in the participant’s diarrheal status (e.g. 
w atery diarrhea versus diarrhea). 
Incomplete 
outcome data 
addressed? 
Unclear The data of the 32 participants w ho were excluded does not appear in any analysis (e.g. ITT) and 
reasons for this exclusion are not mentioned. 
Free of selective 
reporting? 
Unclear Researchers report that adverse effects were observed but little/no information w as given 
regarding this in the results section.   
Free of other bias? Yes  
 
OZKAN 2007 
ITEM Authors 
judgments 
Description 
Adequate 
sequence 
generation? 
Unclear A general statement w as made that patients w ere randomly allocated to one of tw o treatment 
groups, but no further details on how  this was done is described. 
Adequate 
allocation 
concealment? 
Unclear No details on how  allocation concealment w as guaranteed are provided. 
Adequate blinding 
of participants and 
personnel? 
Yes The control group (group 2) w as given a placebo treatment that had identical characteristics and 
appearance. 
Adequate blinding 
of outcome 
assessment?  
Unclear No details on the outcome assessment technique used have been provided. 
Incomplete 
outcome data 
addressed? 
Unclear No information on any incomplete data. 
Free of selective 
reporting? 
Yes All outcomes w ere reported on. 
Free of other bias? Yes  
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RIAZ 2010 
ITEM Authors 
judgments 
Description 
Adequate 
sequence 
generation? 
Unclear A general comment w ith no further detail is given stating that after informed consent w as 
obtained, the participants w ere randomly given wither a placebo or intervention. 
Adequate 
allocation 
concealment? 
Yes A non-departmental colleague not involved in the study randomized these identical packets of 
placebo or Saccharomyces boulardii. 
Adequate blinding 
of participants and 
personnel? 
Yes Placebo or Saccharomyces boulardii in identical packets mixed w ith puffed rice powder. 
Adequate blinding 
of outcome 
assessment?  
Yes Use clear discharge and recovery criteria, observed by the mother (w ho was blinded) and then 
personnel. 
Incomplete 
outcome data 
addressed? 
Yes ITT and PP analysis w ere done. 
Free of selective 
reporting? 
Yes All stated outcomes w ere reported on. 
Free of other bias? Yes  
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APPENDIX 6.10: Forest plot: mean number of stools per day (Saccharomyces boulardii versus control) 
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APPENDIX 6.11: Forest plot: frequency of diarrhea during the first three days post intervention 
(Saccharomyces boulardii versus control) 
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APPENDIX 6.12: Forest plot: number having less than three stools per day during the first 7 days after 
starting intervention (Saccharomyces boulardii versus control) 
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APPENDIX 6.13: Forest plot: number having solid stools during the first 7 days after starting 
intervention (Saccharomyces boulardii versus control) 
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